Anti-viral vectors

Abstract

A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.

Description

FIELD OF THE INVENTION

The present invention relates to novel viral vectors capable of delivering anti-viral inhibitory RNA molecules to target cells.

BACKGROUND TO THE INVENTION

The application of gene therapy to the treatment of AIDS and HIV infection has been discussed widely (Lever, 1995). The types of therapeutic gene proposed usually fall into one of two broad categories. In the first the gene encodes protein products that inhibit the virus in a number of possible ways. One example of such a protein is the RevM10 derivative of the HIV Rev protein. The RevM10 protein acts as a transdominant negative mutant and so competitively inhibits Rev function in the virus. Like many of the protein-based strategies, the RevM10 protein is a derivative of a native HIV protein. While this provides the basis for the anti-HIV effect, it also has serious disadvantages. In particular, this type of strategy demands that in the absence of the virus there is little or no expression of the gene. Otherwise, healthy cells harbouring the gene become a target for the host cytotoxic T lymphocyte (CTL) system, which recognises the foreign protein. The second broad category of therapeutic gene circumvents these CTL problems. The therapeutic gene encodes inhibitory RNA molecules; RNA is not a target for CTL recognition.

There are several types of inhibitory RNA molecules known: anti-sense RNA, ribozyrnes, competitive decoys and external guide sequences (EGSs).

External guide sequences, first identified by Forster and Altman (1990), are RNA sequences that are capable of directing the cellular protein RNase P to cleave a particular RNA sequence. In vivo, they are found as part of precursor tRNAs where they function to direct cleavage by the cellular riboprotein RNase P in vivo of the tRNA precursor to form mature tRNA. However, in principle, any RNA can be targeted by a custom-designed EGS RNA for specific cleavage by RNase P in vitro or in viva. For example, Yuan et al. (1992) demonstrate a reduction in the levels of chloramphenicol activity in cells in tissue culture as a result of introducing an appropriately designed EGS.

In recent years a number of laboratories have developed retroviral vector systems based on HIV. In the context of anti-HIV gene therapy these vectors have a number of advantages over the more conventional murine based vectors such as murine leukaemia virus (MLV) vectors. Firstly, HIV vectors would target precisely those cells that are susceptible to HIV infection. Secondly, the HIV-based vector would transduce cells such as macrophages that are normally refractory to transduction by murine vectors. Thirdly, the anti-HIV vector genome would be propagated through the CD4+ cell population by any virus (HIV) that escaped the therapeutic strategy. This is because the vector genome has the packaging signal that will be recognised by the viral particle packaging system. These various attributes make HIV-vectors a powerful tool in the field of anti-HIV gene therapy.

A combination of inhibitory RNA molecules and an HIV-based vector would be attractive as a therapeutic strategy. However, until now this has not been possible. Vector particle production takes place in producer cells which express the packaging components of the particles and package the vector genome. The inhibitory RNA sequences that are designed to destroy the viral RNA would therefore also interrupt the expression of the components of the HIV-based vector system during vector production. The present invention aims to overcome this problem.

SUMMARY OF THE INVENTION

It is therefore an object of the invention to provide a system and method for producing viral particles, in particular HIV particles, which carry nucleotide constructs encoding inhibitory RNA molecules such as external guide sequences, optionally together with other classes of inhibitory RNA molecules such as ribozyrnes and/or antisense RNAs directed against a corresponding virus, such as HIV, within a target cell, that overcomes the above-mentioned problems. The system includes both a viral genome encoding the inhibitory RNA molcules and nucleotide constructs encoding the components required for packaging the viral genome in a producer cell. However, in contrast to the prior art, although the packaging components have substantially the same amino acid sequence as the corresponding components of the target virus, the inhibitory RNA molecules do not affect production of the viral particles in the producer cells because the nucleotide sequence of the packaging components used in the viral system have been modified to prevent the inhibitory RNA molecules from effecting cleavage or degradation of the RNA transcripts produced from the constructs. Such a viral particle may be used to treat viral infections, in particular HIV infections.

Accordingly the present invention provides a viral vector system comprising:

(i) a first nucleotide sequence encoding an external guide sequence capable of binding to and effecting the cleavage by RNase P of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; and

(ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that the third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by the external guide sequence.

Preferably, said system further comprises at least one further first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, wherein the gene product is selected from an external guide sequence, a ribozyme and an anti-sense ribonucleic acid.

In another aspect, the present invention provides a viral vector production system comprising:

(i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles;

(ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product;

wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

Preferably, in addition to an external guide sequence, at least one gene product is selected from a ribozyme and an anti-sense ribonucleic acid, preferably a ribozyme.

Preferably, the viral vector is a retroviral vector, more preferably a lentiviral vector, such as an HIV vector. The second nucleotide sequence and the third nucleotide sequences are typically from the same viral species, more preferably from the same viral strain. Generally, the viral genome is also from the same viral species, more preferably from the same viral strain.

In the case of retroviral vectors, the polypeptide required for the assembly of viral particles is selected from gag, pol and env proteins. Preferably at least the gag and pol sequences are lentiviral sequences, more preferably HIV sequences. Alternatively, or in addition, the env sequence is a lentiviral sequence, more preferably an HIV sequence.

In a preferred embodiment, the third nucleotide sequence is resistant to cleavage directed by the gene product as a result of one or more conservative alterations in the nucleotide sequence which remove cleavage sites recognised by the at least one gene product and/or binding sites for the at least one gene product. For example, where the gene product is an EGS, the third nucleotide sequence is adapted to prevent EGS binding and/or to remove the RNase P consensus cleavage site. Alternatively, where the gene product is a ribozyme, the third nucleotide sequence is adapted to be resistant to cleavage by the ribozyme.

Preferably the third nucleotide sequence is codon optimised for expression in host cells. The host cells, which term includes producer cells and packaging cells, are typically mammalian cells.

In a particularly preferred embodiment, (i) the viral genome is an HIV genome comprising nucleotide sequences encoding anti-HIV EGSs and optionally anti-HIV ribozyme sequences directed against HIV packaging component sequences (such as gag.pol) in a target HIV and (ii) the viral system for producing packaged HIV particles further comprises nucleotide constructs encoding the same packaging components (such as gag.pol proteins) as in the target HIV wherein the sequence of the nucleotide constructs is different from that found in the target HIV so that the anti-HIV EGS and anti-HIV ribozyme sequences cannot effect cleavage or degradation of the gag.pol transcripts during production of the HIV particles in producer cells.

The present invention also provides a viral particle comprising a viral vector according to the present invention and one or more polypeptides encoded by the third nucleotide sequences according to the present invention. For example the present invention provides a viral particle produced using the viral vector production system of the invention.

In another aspect, the present invention provides a method for producing a viral particle which method comprises introducing into a host cell (i) a viral genome vector according to the present invention; (ii) one or more third nucleotide sequences according to the present invention; and (iii) nucleotide sequences encoding the other essential viral packaging components not encoded by the one or more third nucleotide sequences.

The present invention further provides a viral particle produced using by the method of the invention.

The present invention also provides a pharmaceutical composition comprising a viral particle according to the present invention together with a pharmaceutically acceptable carrier or diluent.

The viral system of the invention or viral particles of the invention may be used to treat viral infections, particularly retroviral infections such as lentiviral infections including HIV infections. Thus the present invention provides a method of treating a viral infection which method comprises administering to a human or animal patient suffering from the viral infection an effective amount of a viral system, viral particle or pharmaceutical composition of the present invention.

The invention relates in particular to HIV-based vectors carrying anti-HIV EGSs. However, the invention can be applied to any other virus, in particular any other lentivirus, for which treatment by gene therapy may be desirable. The invention is illustrated herein for HIV, but this is not considered to limit the scope of the invention to HIV-based anti-HIV vectors.

DETAILED DESCRIPTION OF THE INVENTION

The term “viral vector” refers to a nucleotide construct comprising a viral genome capable of being transcribed in a host cell, which genome comprises sufficient viral genetic information to allow packaging of the viral RNA genome, in the presence of packaging components, into a viral particle capable of infecting a target cell. Infection of the target cell includes reverse transcription and integration into the target cell genome, where appropriate for particular viruses. The viral vector in use typically carries heterologous coding sequences (nucleotides of interest) which are to be delivered by the vector to the target cell, for example a first nucleotide sequence encoding an EGS. A viral vector is incapable of independent replication to produce infectious viral particles within the final target cell.

The term “viral vector system” is intended to mean a kit of parts which can be used when combined with other necessary components for viral particle production to produce viral particles in host cells. For example, the first nucleotide sequence may typically be present in a plasmid vector construct suitable for cloning the first nucleotide sequence into a viral genome vector construct. When combined in a kit with a third nucleotide sequence, which will also typically be present in a separate plasmid vector construct, the resulting combination of plasmid containing the first nucleotide sequence and plasmid containing the third nucleotide sequence comprises the essential elements of the invention. Such a kit may then be used by the skilled person in the production of suitable viral vector genome constructs which when transfected into a host cell together with the plasmid containing the third nucleotide sequence, and optionally nucleic acid constructs encoding other components required for viral assembly, will lead to the production of infectious viral particles.

Alternatively, the third nucleotide sequence may be stably present within a packaging cell line that is included in the kit.

The kit may include the other components needed to produce viral particles, such as host cells and other plasmids encoding essential viral polypeptides required for viral assembly. By way of example, the kit may contain (i) a plasmid containing a first nucleotide sequence encoding an anti-HIV EGS and (ii) a plasmid containing a third nucleotide sequence encoding a modified HIV gag.pol construct which cannot be cleaved by the anti-HIV ribozyme. Optional components would then be (a) an HIV viral genome construct with suitable restriction enzyme recognition sites for cloning the first nucleotide sequence into the viral genome; (b) a plasmid encoding a VSV-G env protein. Alternatively, nucleotide sequence encoding viral polypeptides required for assembly of viral particles may be provided in the kit as packaging cell lines comprising the nucleotide sequences, for example a VSV-G expressing cell line.

The term “viral vector production system” refers to the viral vector system described above wherein the first nucleotide sequence has already been inserted into a suitable viral vector genome.

Viral vectors are typically retroviral vectors, in particular lentiviral vectors such as HIV vectors. The retroviral vector of the present invention may be derived from or may be derivable from any suitable retrovirus. A large number of different retroviruses have been identified. Examples include: murine leukemia virus (MLV), human immunodeficiency virus (HIV), simian immunodeficiency virus, human T-cell leukemia virus (HTLV). equine infectious anaemia virus (EIAV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukemia virus (A-MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV). A detailed list of retroviruses may be found in Coffin et al., 1997, “Retroviruses”, Cold Spring Harbour Laboratory Press Eds: J M Coffin, S M Hughes, H E Varmus pp 758-763.

Details on the genomic structure of some retroviruses may be found in the art. By way of example, details on HIV and Mo-MLV may be found from the NCBI Genbank (Genome Accession Nos. AF033819 and AF033811, respectively).

The lentivirus group can be split even further into “primate” and “non-primate”. Examples of primate lentiviruses include human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype “slow virus” visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).

The basic structure of a retrovirus genome is a 5′ LTR and a 3′ LTR, between or within which are located a packaging signal to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome and gag, pol and env genes encoding the packaging components—these are polypeptides required for the assembly of viral particles. More complex retroviruses have additional features, such as rev and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell.

In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral genes. Encapsidation of the retroviral RNAs occurs by virtue of a psi sequence located at the 5′ end of the viral genome.

The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3′ end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5′ end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.

In a defective retroviral vector genome gag, pol and env may be absent or not functional. The R regions at both ends of the RNA are repeated sequences. U5 and U3 represent unique sequences at the 5′ and 3′ ends of the RNA genome respectively.

In a typical retroviral vector for use in gene therapy, at least part of one or more of the gag, pol and env protein coding regions essential for replication may be removed from the virus. This makes the retroviral vector replication-defective. The removed portions may even be replaced by a nucleotide sequence of interest (NOI), such as a first nucleotide sequence of the invention, to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs—resulting in, for example, a therapeutic and/or a diagnostic effect. Thus; the transfer of an NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest—such as a targeted cell or a targeted cell population.

A minimal retroviral genome for use in the present invention will therefore comprise (5′) R—U5—one or more first nucleotide sequences—U3-R (3′). However, the plasmid vector used to produce the retroviral genome within a host cell/packaging cell will also include transcriptional regulatory control sequences operably linked to the retroviral genome to direct transcription of the genome in a host cell/packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed retroviral sequence, i.e. the 5′ U3 region, or they may be a heterologous promoter such as another viral promoter, for example the CMV promoter.

Some retroviral genomes require additional sequences for efficient virus production. For example, in the case of HIV, rev and RRE sequence are preferably included. However the requirement for rev and RRE can be reduced or eliminated by codon optimisation.

Once the retroviral vector genome is integrated into the genome of its target cell as proviral DNA, the ribozyme sequences need to be expressed. In a retrovirus, the promoter is located in the 5′ LTR U3 region of the provirus. In retroviral vectors, the promoter driving expression of a therapeutic gene may be the native retroviral promoter in the 5′ U3 region, or an alternative promoter engineered into the vector. The alternative promoter may physically replace the 5′ U3 promoter native to the retrovirus, or it may be incorporated at a different place within the vector genome such as between the LTRs.

Thus, the first nucleotide sequence will also be operably linked to a transcriptional regulatory control sequence to allow transcription of the first nucleotide sequence to occur in the target cell. The control sequence will typically be active in mammalian cells. The control sequence may, for example, be a viral promoter such as the natural viral promoter or a CMV promoter or it may be a mammalian promoter. It is particularly preferred to use a promoter that is preferentially active in a particular cell type or tissue type in which the virus to be treated primarily infects. Thus, in one embodiment, a tissue-specific regulatory sequences may be used. The regulatory control sequences driving expression of the one or more first nucleotide sequences may be constitutive or regulated promoters.

Replication-defective retroviral vectors are typically propagated, for example to prepare suitable titres of the retroviral vector for subsequent transduction, by using a combination of a packaging or helper cell line and the recombinant vector. That is to say, that the three packaging proteins can be provided in trans.

A “packaging cell line” contains one or more of the retroviral gag, pol and env genes. The packaging cell line produces the proteins required for packaging retroviral DNA but it cannot bring about encapsidation due to the lack of a psi region. However, when a recombinant vector carrying an NOI and a psi region is introduced into the packaging cell line, the helper proteins can package the psi-positive recombinant vector to produce the recombinant virus stock. This virus stock can be used to transduce cells to introduce the NOI into the genome of the target cells. It is preferred to use a psi packaging signal, called psi plus, that contains additional sequences spanning from upstream of the splice donor to downstream of the gag start codon (Bender et al., 1987) since this has been shown to increase viral titres.

The recombinant virus whose genome lacks all genes required to make viral proteins can tranduce only once and cannot propagate. These viral vectors which are only capable of a single round of transduction of target cells are known as replication defective vectors.

Hence, the NOI is introduced into the host/target cell genome without the generation of potentially harmful retrovirus. A summary of the available packaging lines is presented in Coffin et al., 1997 (ibid).

Retroviral packaging cell lines in which the gag, pol and env viral coding regions are carried on separate expression plasmids that are independently transfected into a packaging cell line are preferably used. This strategy, sometimes referred to as the three plasmid transfection method (Soneoka et al., 1995) reduces the potential for production of a replication-competent virus since three recombinant events are required for wild type viral production. As recombination is greatly facilitated by homology, reducing or eliminating homology between the genomes of the vector and the helper can also be used to reduce the problem of replication-competent helper virus production.

An alternative to stably transfected packaging cell lines is to use transiently transfected cell lines. Transient transfections may advantageously be used to measure levels of vector production when vectors are being developed. In this regard, transient transfection avoids the longer time required to generate stable vector-producing cell lines and may also be used if the vector or retroviral packaging components are toxic to cells. Components typically used to generate retroviral vectors include a plasmid encoding the gag/pol proteins, a plasmid encoding the env protein and a plasmid containing an NOI. Vector production involves transient transfection of one or more of these components into cells containing the other required components. If the vector encodes toxic genes or genes that interfere with the replication of the host cell, such as inhibitors of the cell cycle or genes that induce apotosis, it may be difficult to generate stable vector-producing cell lines, but transient transfection can be used to produce the vector before the cells die. Also, cell lines have been developed using transient transfection that produce vector titre levels that are comparable to the levels obtained from stable vector-producing cell lines (Pear et al., 1993).

Producer cells/packaging cells can be of any suitable cell type. Most commonly, mammalian producer cells are used but other cells, such as insect cells are not excluded. Clearly, the producer cells will need to be capable of efficiently translating the env and gag, pol mRNA. Many suitable producer/packaging cell lines are known in the art. The skilled person is also capable of making suitable packaging cell lines by, for example stably introducing a nucleotide construct encoding a packaging component into a cell line.

As will be discussed below, where the retroviral genome encodes an inhibitory RNA molecule capable of effecting the cleavage of gag, pol and/or env RNA transcripts, the nucleotide sequences present in the packaging cell line, either integrated or carried on plasmids, or in the transiently transfected producer cell line, which encode gag, pol and or env proteins will be modified so as to reduce or prevent binding of the inhibitory RNA molecule(s). In this way, the inhibitory RNA molecule(s) will not prevent expression of components in packaging cell lines that are essential for packaging of viral particles.

It is highly desirable to use high-titre virus preparations in both experimental and practical applications. Techniques for increasing viral titre include using a psi plus packaging signal as discussed above and concentration of viral stocks. In addition, the use of different envelope proteins, such as the G protein from vesicular-stomatitis virus has improved titres following concentration to 10 9 per ml (Cosset et al., 1995). However, typically the envelope protein will be chosen such that the viral particle will preferentially infect cells that are infected with the virus which it desired to treat. For example where an HIV vector is being used to treat HIV infection, the env protein used will be the HIV env protein.

Suitable first nucleotide sequences for use according to the present invention encode gene products that result in the cleavage and/or enzymatic degradation of a target nucleotide sequence, which will generally be a ribonucleotide. As particular examples, EGSs, ribozymes, and antisense sequences may be mentioned, more specifically EGSs.

External guide sequences (EGSs) are RNA sequences that bind to a complementary target sequence to form a loop in the target RNA sequence, the overall structure being a substrate for RNaseP-mediated cleavage of the target RNA sequence. The structure that forms when the EGS anneals to the target RNA is very similar to that found in a tRNA precursor. The the natural activity of RNaseP can be directed to cleave a target RNA by designing a suitable EGS. The general rules for EGS design are as follows, with reference to the generic EGSs shown in FIG. 9 B:

Rules for EGS Design in Mammalian Cells (See FIG. 9 B)

Target sequence—All tRNA precursor molecules have a G immediately 3′ of the RNaseP cleavage site (i.e. the G forms a base pair with the C at the top of the acceptor stem prior to the ACCA sequence). In addition a U is found 8 nucleotides downstream in all tRNAs. (i.e. G at position 1, U at position 8). A pyrimidine may be preferred 5′ of the cut site. No other specific target sequences are required.

EGS sequence—A 7 nucleotide ‘acceptor stem’ analogue is optimal (5′ hybridising arm). A 4 nucleotide ‘D-stem’ analogue is preferred (3′ hybridising arm). Variation in this length may alter the reaction kinetics. This will be specific to each target site. A consensus ‘T-stem and loop’ analogue is essential. Minimal 5′ and 3′ non-pairing sequences are preferred to reduce the potential for undesired folding of the EGS RNA.

Deletion of the ‘anti-codon stem and loop’ analogue may be beneficial. Deletion of the variable loop can also be tolerated in vitro but an optimal replacement loop for the deletion of both has not been defined in vivo.

As with ribozymes, described below, it is preferred to use more than one EGS. Preferably, a plurality of EGSs is employed, together capable of cleaving gag, pol and env RNA of the native retrovirus at a plurality of sites. Since HIV exists as a population of quasispecies, not all of the target sequences for the EGSs will be included in all HIV variants. The problem presented by this variability can be overcome by using multiple EGs. Multiple EGSs can be included in series in a single vector and can function independently when expressed as a single RNA sequence. A single RNA containing two or more EGSs having different target recognition sites may be referred to as a multitarget EGS.

Further guidance may be obtained by reference to, for example, Werner et al. (1997); Werner et al. (1998); Ma et al. (1998) and Kawa et al. (1998).

Ribozymes are RNA enzymes which cleave RNA at specific sites. Ribozyrnes can be engineered so as to be specific for any chosen sequence containing a ribozyme cleavage site. Thus, ribozymes can be engineered which have chosen recognition sites in transcribed viral sequences. By way of an example, ribozymes encoded by the first nucleotide sequence recognise and cleave essential elements of viral genomes required for the production of viral particles, such as packaging components. Thus, for retroviral genomes, such essential elements include the gag, pod and env gene products. A suitable ribozyme capable of recognising at least one of the gag, pol and env gene sequences, or more typically, the RNA sequences transcribed from these genes, is able to bind to and cleave such a sequence. This will reduce or prevent production of the gal, pol or env protein as appropriate and thus reduce or prevent the production of retroviral particles.

Ribozymes come in several forms, including hammerhead, hairpin and hepatitis delta antigenomic ribozymes. Preferred for use herein are hammerhead ribozymes, in part because of their relatively small size, because the sequence requirements for their target cleavage site are minimal and because they have been well characterised. The ribozymes most commonly used in research at present are hammerhead and hairpin ribozyrnes.

Each individual ribozyme has a motif which recognises and binds to a recognition site in the target RNA. This motif takes the form of one or more “binding arms”, generally two binding arms. The binding arms in hammerhead ribozymes are the flanking sequences Helix I and Helix III, which flank Helix II. These can be of variable length, usually between 6 to 10 nucleotides each, but can be shorter or longer. The length of the flanking sequences can affect the rate of cleavage. For example, it has been found that reducing the total number of nucleotides in the flanking sequences from 20 to 12 can increase the turnover rate of the ribozyme cleaving a HIV sequence, by 10-fold (Goodchild et al., 1991). A catalytic motif in the ribozyme Helix II in hammerhead ribozymes cleaves the target RNA at a site which is referred to as the cleavage site. Whether or not a ribozyme will cleave any given RNA is determined by the presence or absence of a recognition site for the ribozyme containing an appropriate cleavage site.

Each type of ribozyme recognises its own cleavage site. The hammerhead ribozyme cleavage site has the nucleotide base triplet GUX directly upstream where G is guanine, U is uracil and X is any nucleotide base. Hairpin ribozymes have a cleavage site of BCUGNYR, where B is any nucleotide base other than adenine, N is any nucleotide, Y is cytosine or thymine and R is guanine or adenine. Cleavage by hairpin ribozyrnes takes places between the G and the N in the cleavage site.

The nucleic acid sequences encoding the packaging components (the “third nucleotide sequences”) may be resistant to the ribozyme or ribozymes because they lack any cleavage sites for the ribozyme or ribozymes. This prohibits enzymatic activity by the ribozyme or ribozymes and therefore there is no effective recognition site for the ribozyme or ribozymes. Alternatively or additionally, the potential recognition sites may be altered in the flanking sequences which form the part of the recognition site to which the ribozyme binds. This either eliminates binding of the ribozyme motif to the recognition site, or reduces binding capability enough to destabilise any ribozyme-target complex and thus reduce the specificity and catalytic activity of the ribozyme. Where the flanking sequences only are altered, they are preferably altered such that catalytic activity of the ribozyme at the altered target sequence is negligible and is effectively eliminated.

Preferably, a series of several anti-HIV ribozymes is employed in the invention. These can be any anti-HIV ribozymes but must include one or more which cleave the RNA that is required for the expression of gag, pot or env. Preferably, a plurality of ribozymes is employed, together capable of cleaving gag, pot and env RNA of the native retrovirus at a plurality of sites. Since HIV exists as a population of quasispecies, not all of the target sequences for the ribozymes will be included in all HIV variants. The problem presented by this variability can be overcome by using multiple ribozymes. Multiple ribozymes can be included in series in a single vector and can function independently when expressed as a single RNA sequence. A single RNA containing two or more ribozymes having different target recognition sites may be referred to as a multitarget ribozyme. The placement of ribozymes in series has been demonstrated to enhance cleavage. The use of a plurality of ribozymes is not limited to treating HIV infection but may be used in relation to other viruses, retroviruses or otherwise.

Antisense technology is well known on the art. There are various mechanisms by which antisense sequences are believed to inhibit gene expression. One mechanism by which antisense sequences are believed to function is the recruitment of the cellular protein RNaseH to the target sequence/antisense construct heteroduplex which results in cleavage and degradation of the heteroduplex. Thus the antisense construct, by contrast to ribozymes, can be said to lead indirectly to cleavage/degradation of the target sequence. Thus according to the present invention, a first nucleotide sequence may encode an antisense RNA that binds to either a gene encoding an essential/packaging component or the RNA transcribed from said gene such that expression of the gene is inhibited, for example as a result of RNaseH degradation of a resulting heteroduplex. It is not necessary for the antisense construct to encode the entire complementary sequence of the gene encoding an essential/packaging component—a portion may suffice. The skilled person will easily be able to determine how to design a suitable antisense construct.

By contrast, the nucleic acid sequences encoding the essential/packaging components of the viral particles required for the assembly of viral particles in the host cells/producer cells/packaging cells (the third nucleotide sequences) are resistant to the inhibitory RNA molecules encoded by the first nucleotide sequence. For example in the case of ribozymes, resistance is typically by virtue of alterations in the sequences which eliminate the ribozyme recognition sites. At the same time, the amino acid coding sequence for the essential/packaging components is retained so that the viral components encoded by the sequences remain the same, or at least sufficiently similar that the function of the essential/packaging components is not compromised.

The term “viral polypeptide required for the assembly of viral particles” means a polypeptide normally encoded by the viral genome to be packaged into viral particles, in the absence of which the viral genome cannot be packaged. For example, in the context of retroviruses such polypeptides would include gag, pol and env. The terms “packaging component” and “essential component” are also included within this definition.

In the case of antisense sequences, the third nucleotide sequence differs from the second nucleotide sequence encoding the target viral packaging component antisense sequence to the extent that although the antisense sequence can bind to the second nucleotide sequence, or transcript thereof, the antisense sequence can not bind effectively to the third nucleotide sequence or RNA transcribed from therefrom The changes between the second and third nucleotide sequences will typically be conservative changes, although a small number of amino acid changes may be tolerated provided that, as described above, the function of the essential/packaging components is not significantly impaired.

Preferably, in addition to eliminating the inhibitory RNA recognition sites, the alterations to the coding sequences for the viral components improve the sequences for codon usage in the mammalian cells or other cells which are to act as the producer cells for retroviral vector particle production. This improvement in codon usage is referred to as “codon optimisation”. Many viruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms.

Thus preferably, the sequences encoding the packaging components are codon optimised. More preferably, the sequences are codon optimised in their entirety. Following codon optimisation, it is found that there are numerous sites in the wild type gag, pol and env sequences which can serve as inhibitory RNA recognition sites and which are no longer present in the sequences encoding the packaging components. In an alternative but less practical strategy, the sequences encoding the packaging components can be altered by targeted conservative alterations so as to render them resistant to selected inhibitory RNAs capable of effecting the cleavage of the wild type sequences.

An additional advantage of codon optimising HIV packaging components is that this can increase gene expression. In particular, it can render gag, pol expression Rev independent so that rev and RRE need not be included in the genome (Haas et at., 1996). Rev-independent vectors are therefore possible. This in turn enables the use of anti-rev or RRE factors in the retroviral vector.

As described above, the packaging components for a retroviral vector include expression products of gag, pol and env genes. In accordance with the present invention, gag and pol employed in the packaging system are derived from the target retrovirus on which the vector genome is based. Thus, in the RNA transcript form, gag and pol would normally be cleavable by the ribozymes present in the vector genome. The env gene employed in the packaging system may be derived from a different virus, including other retroviruses such as MLV and non-retroviruses such as VSV (a Rhabdovirus), in which case it may not need any sequence alteration to render it resistant to cleavage effected by the inhibitory RNA(s). Alternatively, env may be derived from the same retrovirus as gag and pol, in which case any recognition sites for the inhibitory RNA(s) will need to be eliminated by sequence alteration.

The process of producing a retroviral vector in which the envelope protein is not the native envelope of the retrovirus is known as “pseudotyping”. Certain envelope proteins, such as MLV envelope protein and vesicular stomatitis virus G (VSV-G) protein, pseudotype retroviruses very weft. Pseudotyping can be useful for altering the target cell range of the retrovirus. Alternatively, to maintain target cell specificity for target cells infected with the a particular virus it is desired to treat, the envelope protein may be the same as that of the target virus, for example HIV.

Other therapeutic coding sequences may be present along with the first nucleotide sequence or sequences. Other therapeutic coding sequences include, but are not limited to, sequences encoding cytokines, hormones, antibodies, immunoglobulin fusion proteins, enzymes, immune co-stimulatory molecules, anti-sense RNA, a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen, a single chain antibody, tumour suppresser protein and growth factors. When included, such coding sequences are operatively linked to a suitable promoter, which may be the promoter driving expression of the first nucleotide sequence or a different promoter or promoters.

Thus the invention comprises two components. The first is a genome construction that will be packaged by viral packaging components and which carries a series of anti-viral inhibitory RNA molecules such as anti-HIVEGs. These could be any anti-HIV EGSs but the key issue for this invention is that some of them result in cleavage of RNA that is required for the expression of native or wild type HIV gag, pol or env coding sequences. The second component is the packaging system which comprises a cassette for the expression of HIV gag, pol and a cassette either for HIV env or an envelope gene encoding a pseudotyping envelope protein—the packaging system being resistant to the inhibitory RNA molecules.

The viral particles of the present invention, and the viral vector system and methods used to produce may thus be used to treat or prevent viral infections, preferably retroviral infections, in particular lentiviral, especially HIV, infections. Specifically, the viral particles of the invention, typically produced using the viral vector system of the present invention may be used to deliver inhibitory RNA molecules to a human or animal in need of treatment for a viral infection.

Alternatively, or in addition, the viral production system may be used to transfect cells obtained from a patient ex vivo and then returned to the patient. Patient cells transfected ex vivo may be formulated as a pharmaceutical composition (see below) prior to readministration to the patient.

Preferably the viral particles are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Thus, the present invention also provides a pharmaceutical composition for treating an individual, wherein the composition comprises a therapeutically effective amount of the viral particle of the present invention, together with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The pharmaceutical composition may be for human or animal usage.

The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The pharmaceutical compositions may comprise as—or in addition to—the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the viral entry into the target site (such as for example a lipid delivery system).

The pharmaceutical composition may be formulated for parenteral, intramuscular, intravenous, intracranial, subcutaneous, oral, intraocular or transdermal administration.

Where appropriate, the pharmaceutical compositions can be administered by any one or more of inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

The amount of virus administered is typically in the range of from 10 3 to 10 10 pfu, preferably from 10 5 to 10 8 pfu, more preferably from 10 6 to 10 7 pfu. When injected, typically 1-10 μl of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.

When the polynucleotide/vector is administered as a naked nucleic acid, the amount of nucleic acid administered is typically in the range of from 1 μg to 10 mg, preferably from 100 μg to 1 mg.

Where the first nucleotide sequence (or other therapeutic sequence) is under the control of an inducible regulatory sequence, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the NOT is stopped. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene expression via its effect on the tet repressor/VP16 fusion protein.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention. The Examples refer to the Figures. In the Figures:

FIG. 1 shows schematically ribozyrnes inserted into four different HIV vectors;

FIG. 2 shows schematically how to create a suitable 3′ LTR by PCR;

FIG. 3 shows the codon usage table for wild type HIV gag,pol of strain HXB2 (accession number: K03455).

FIG. 4 shows the codon usage table of the codon optimised sequence designated gag,pol-SYNgp.

FIG. 5 shows the codon usage table of the wild type HIV env called env-mn.

FIG. 6 shows the codon usage table of the codon optimised sequence of HIV env designated SYNgp160 mn

FIG. 7 shows three plasmid constructs for use in the invention.

FIG. 8 shows the principle behind two systems for producing retroviral vector particles.

FIG. 9A shows an EGS based on tyrosyl t-RNA

FIG. 9B shows a consensus EGS sequence.

FIG. 10 shows twelve different anti-HIV EGS constructs.

FIG. 11 is a schematic representation of pDozenEgs and construction of pH4DozenEgs.

The invention will now be further described in the Examples which follow, which are intended as an illustration only and do not limit the scope of the invention.

EXAMPLES

Reference Example 1—Construction of a Ribozyme-encoding Genome

The HIV gag.pol sequence was codon optimised (FIG. 4 and SEQ I.D. No. 1) and synthesised using overlapping oligos of around 40 nucleotides. This has three advantages. Firstly it allows an HIV based vector to carry ribozymes and other therapeutic factors. Secondly the codon optimisation generates a higher vector titre due to a higher level of gene expression. Thirdly gag.pol expression becomes rev independent which allows the use of anti-rev or RRE factors.

Conserved sequences within gag.pol were identified by reference to the HIV Sequence database at Los Alamos National Laboratory (http:// hiv-web.lanl.gov/) and used to design ribozymes. Because of the variability between subtypes of HIV-1 the ribozymes were designed to cleave the predominant subtype within North America, Latin America and the Caribbean, Europe, Japan and Australia; that is subtype B. The sites chosen were cross-referenced with the synthetic gagpol sequence to ensure that there was a low possibility of cutting the codon optimised gagpol mRNA. The ribozyrnes were designed with XhoI and

SalI sites at the 5′ and 3′ end respectively. This allows the construction of separate and tandem ribozymes.

The ribozymes are hammerhead (Riddell et al., 1996) structures of the following general structure:

(SEQ ID NO: 15)
Helix I            Helix II             Helix III
5′-NNNNNNNN˜   CUGAUGAGGCCGAAAGGCCGAA   ˜NNNNNNNN˜

The catalytic domain of the ribozyme (Helix II) can tolerate some changes without reducing catalytic turnover.

The cleavage sites, targeting gag and pol with the essential GUX triplet (where X is any nucleotide base) are as follows:

GAG 1 5′ UAGUAAGAAUGUAUAGCCCUAC (SEQ ID NO: 16)

GAG 2 5′ AACCCAGAUUGUAAGACUAUUU (SEQ ID NO: 17)

GAG 3 5′ UGUUUCAAUUGUGGCAAAGAAG (SEQ ID NO: 18)

GAG 4 5′ AAAAAGGGCUGUUGGAAAUGUG (SEQ ID NO: 19)

POL 1 5′ ACGACCCCUCGUCACAAUAAAG (SEQ ID NO: 20)

POL 2 5′ GGAAUUGGAGGUUUUAUCAAAG (SEQ ID NO: 21)

POL 3 5′ AUAUUUUUCAGUUCCCUUAGAU (SEQ ID NO. 22)

POL 4 5′ UGGAUGAUUUGUAUGUAGGAUC (SEQ ID NO: 23)

POL 5 5° CUUUGGAUGGGUUAUGAACUCC (SEQ ID NO: 24)

POL 6 5° CAGCUGGACUGUCAAUGACAUA (SEQ ID NO: 25)

POL 7 5′ AACUUUCUAUGUAGAUGGGGCA (SEQ ID NO: 26)

POL 8 5′ AAGGCCGCCUGUUGGUGGGCAG (SEQ ID NO: 27)

POL 9 5′ UAAGACAGCAGUACAAAUGGCA (SEQ ID NO: 28)

The ribozymes are inserted into four different HIV vectors (pH4 (Gervaix et al., 1997), pH6, pH4.1, or pH6.1) (FIG. 1 ). In pH4 and pH6, transcription of the ribozymes is driven by an internal HCMV promoter (Foecking et al., 1986). From pH4.1 and pH6.1, the ribozymes are expressed from the 5′ LTR. The major difference between pH4 and pH6 (and pH4.1 and pH6.1) resides in the 3′ LTR in the production plasmid. pH4 and pH4.1 have the HIV U3 in the 3′ LTR. pH6 and pH6.1 have HCMV in the 3′LTR. The HCMV promoter replaces most of the U3 and will drive expression at high constitutive levels while the HIV-1 U3 will support a high level of expression only in the presence of Tat.

The HCMV/HIV-1 hybrid 3′ LTR is created by recombinant PCR with three PCR primers (FIG, 2 ), The first round of PCR is performed with RIB1 and RIB2 using pH4 (Kim et al., 1998) as the template to amplify the HIV-1 HXB2 sequence 8900-9123. The second round of PCR makes the junction between the 4′ end of the HIV-1 U3 and the HCMV promoter by amplifying the hybrid 5′ LTR from pH4. The PCR product from the first PCR reaction and RIB3 serves as the 5′ primer and 3′ primer respectively.

RIB1: 5′ CAGCTGCTCGAGCAGCTGAAGCTTGCATGC 3′ (SEQ ID NO: 29)

RIB2: 5′ GTAAGTTATGTAACGGACGATATCTTGTCTTCTT 3′ (SEQ ID NO: 30)

RIB3: 5′ CGCATAGTCGACGGGCCCGCCACTGCTAGAGATTTTC 3′ (SEQ ID NO: 31)

The PCR product is then cut with SphI and SalI and inserted into pH4 thereby replacing the 3′ LTR. The resulting plasmid is designated pH6. To construct pH4.1 and pH6.1, the internal HCMV promoter (SpeI-XhoI) in pH4 and pH6 is replaced with the polycloning site of pBluescript II KS+ (Stratagene) (SpeI-XhoI).

The ribozymes are inserted into the XhoI sites in the genome vector backbones. Any ribozymes in any configuration could be used in a similar way.

Reference Example 2—Construction of a Packaging System

The packaging system can take various forms. In a first form of packaging system, the HIV gag, pol components are co-expressed with the HIV env coding sequence. In this case, both the gag, pol and the env coding sequences are altered such that they are resistant to the anti-HIV ribozymes that are built into the genome. At the same time as altering the codon usage to achieve resistance, the codons can be chosen to match the usage pattern of the most highly expressed mammalian genes. This dramatically increases expression levels and so increases titre. A codon optimised HIV env coding sequence has been described by Haas et al. (1996). In the present example, a modified codon optimised HIV env sequence is used (SEQ I.D. No. 3). The corresponding env expression plasmid is designated pSYNgp 160 mn. The modified sequence contains extra motifs not used by Haas et at. The extra sequences were taken from the HIV env sequence of strain MN and codon optimised. Any similar modification of the nucleic acid sequence would function similarly as long as it used codons corresponding to abundant tRNAs (Zolotukhin et al., 1996) and lead to resistance to the ribozymes in the genome.

In one example of a gag, pol coding sequence with optimised codon usage, overlapping oligonucleotides are synthesised and then ligated together to produce the synthetic coding sequence. The sequence of a wild-type (Genbank accession no. K03455) and synthetic (gagpol-SYNgp) gagpol sequence is shown in SEQ I.D. Nos 1 and 2, respectively and their codon usage is shown in FIGS. 3 and 4 , respectively. The sequence of a wild type env coding sequence (Genbank Accession No. M17449) is given in SEQ I.D. No 3, the sequence of a synthetic codon optimised sequence is given in SEQ. I.D. No. 4 and their codon usage tables are given in FIGS. 5 and 6 , respectively. As with the env coding sequence any gag, pol sequence that achieves resistance to the ribozymes could be used. The synthetic sequence shown is designated gag, pol-SYNgp and has an EcoRI site at the 5′ end and a Notl site at the 3′ end. It is inserted into pClneo (Promega) to produce plasmid pSYNgp.

The sequence of the codon optimised gagpol sequence is shown in SEQ I.D. No. 2. This sequence starts at the ATG and ends at the stop codon of gagpol. The wild type sequence is retained around the frameshift site so that the right amount of gagpol is made.

In addition other constructs can be used that contain the optimised gagpol of pSYNgp but also have differing amounts of the wild type HIV 1 sequence of strain HXB2 (accession number: K03455) at the 5′ end. These constructs are described below (the start ATG of pSYNgp is shown in bold in these sequences).

pSYNgp2 contains the entire leader sequence of HIV-1 (SEQ ID. No. 12).

pSYNgp3 contains the leader sequence of HIV-1 from the major splice donor (SEQ ID. No. 13).

pSYNgp4 contains 20 pb of the leader sequence of HIV-1 upstream of the start codon of ATG (SEQ ID. No. 14).

These constructs may be made by overlapping PCR. Using appropriate restriction enzymes these sequences can be inserted into mammalian expression vectors such as pCI-Neo (Promega). All these gag/pol constructs can be used to supply HIV gag/pol for the generation of viral vectors. These viral vectors can be used to express either EGS molecules or ribozyme molecules or antisense molecules or any peptides or proteins.

In a second form of the packaging system a synthetic gag, pol cassette is coexpressed with a non-HIV envelope coding sequence that produces a surface protein that pseudotypes HIV. This could be for example VSV-G (Ory et al., 1996; Zhu et al 1990), amphotropic MLV env (Chesebro et al., 1990; Spector et al., 1990) or any other protein that would be incorporated into the HIV particle (Valsesia-Wittnan, 1994). This includes molecules capable of targeting the vector to specific tissues. Coding sequences for non-HIV envelope proteins not cleaved by the ribozymes and so no sequence modification is required (although some sequence modification may be desirable for other reasons such as optimisation for codon usage in mammalian cells).

Reference Example 3—Vector Particle Production

Vector particles can be produced either from a transient three-plasmid transfection system similar to that described by Soneoka et al. (1995) or from producer cell lines similar to those used for other retroviral vectors (Ory et al., 1996; Srinivasakumar et al., 1997; Yu et al., 1996). These principles are illustrated in FIGS. 7 and 8 . For example, by using pH6Rz, pSYNgp and pRV67 (VSV-G expression plasmid) in a three plasmid transfection of 293T cells (FIG. 8 ), as described by Soneoka et at. (1995), vector particles designated H6Rz-VSV are produced. These transduce the H6Rz genome to CD4+ cells such as C1866 or Jurkat and produce the multitarget ribozymes. HIV replication in these cells is now severely restricted.

Example 1—Use of External Guide Sequences for Inhibiting HIV

Ribonuclease P is a nuclear localised enzyme consisting of protein and RNA subunits. It has been found in all organisms examined and is one of the most abundant, stable and efficient enzymes in cells. Its enzymatic activity is responsible for the maturation of the 5′ termini of all tRNAs which account for about 2% of the total cellular RNA.

For tRNA processing, it has been shown that RNAse P recognises a secondary structure of the tRNA. However extensive studies have shown that any complex of two RNA molecules which resemble the one tRNA molecule will also be recognised and cleaved by RNase P. Consequently the natural activity of RNase P can and has been successfully re-directed to target other RNA species (see Yaun and Altman, 1994, and references therein). This is achieved by engineering a sequence, containing the flanking motif recognised by RNaseP, to bind the desired target sequence. These sequences are called external guide sequence (EGSs).

Outlined here is a strategy employing the EGS system against HIV RNA. Shown in FIG. 2A , B and C are twelve EGS sequences designed to target twelve separate HIV gag/pol sequences. These target sequences are conserved throughout the clade B of HIV. The sequence numbering in each figure designates the position of the required conserved G of each target sequences based on the HXB2 published sequence.

The external guide sequences shown here all have anticodon stem-loops deleted. These are non-limiting examples; for instance full length 3/4 tRNA based EGSs might be used if preferred (see Yuan and Altman, 1994).

Outlined in SEQ ID. Nos. 5 to 10 (see below) and FIG. 11 is the cloning strategy employed to construct an HIV vector containing the EGSs described in SEQ ID. Nos. 5 to 10. The oligonucleotides prefixed 1, 2, 3, 4, 5 and 6 are respectively annealed together and sequentially cloned into the pSP72 (Promega) cloning vector starting with the oligo. duplex 1/1A being cloned into the XhoI-SalI site such that the EGS 4762 and EGS 4715 are orientated away from the ampicillin gene. The remaining oligonucleotides (with XhoI ends) are subsequently cloned stepwise (starting with oligo. duplex 2/2A, ending with duplex 6/6A) into the unique SalI site (present within the terminus of the each preceding oligonucleotide) to create the plasmid pDOZENEGS. The EGSs from this vector are then transferred by XhoI-SphI digest into the pH4Z similarily cut such that the multiple EGSs cassette replaces the lacZ gene of pH4Z (Kim et al., 1998). The resulting vector is named pH4DOZENEGS (see SEQ ID. No. 11 for complete sequence).

Egs 1/1A (SEQ ID NO. 5)

(SEQ ID NO: 5) 5′-tcgagcccggggatgacgtcatcgacttcgaaggttcgaatccttctactgccaccatttttt cgggcccctactgcagtagctgaagcttccaagcttaggaagatgacggtggtaaaaaa ctctacgtcatcgacttcgaaggttegaatccttccctgtccaccagtcgacc-3′ gagatgcagtagctgaagcttccaagcttaggaagggacaggtggtcagctggagct-5′ SEQ ID NO: 32)

Egs 2/2A (SEQ ID NO. 6)

(SEQ ID NO. 6) 5′-tcgagtattacgtcatcgacttcgaaggttcgaatccttctagattcaccattttttaggaacg cataatgcagtagctgaag cttccaagcttaggaagtactaagtggtaaaaaatccttgc tcatcgacttcg aaggttcgaatccttccagttccaccagtcgacc-3′ agtagctgaagcttccaagcttaggaaggtcaaggtggtcagctggagct-5′ (SEQ ID NO. 33)

Egs 3/3A (SEQ ID NO. 7)

(SEQ ID NO. 7) 5′-tcgaggccaacgtcatcgacttcgaaggttcgaatccttctcttcccaccattttttttcc ccggttgcagtagctgaagcttccaagcttaggaagagaagggtggtaaaaaaaagg ctgaacgtcatcgacttcgaaggttcgaatccttctgctgtcaccagtcgacc-3′ gagatgcagtagctgaagcttccaagcttaggaagggacaggtggtcagctggagct-5′ (SEQ ID NO. 34)

Egs 4/4 (SEQ ID NO. 8)

(SEQ ID NO. 8) 5′-tcgagggctacgtcatcgacttcgaaggttcgaatccttcttgcttcaccatttttt cccgatgcagtagctgaatgcttccaagcttaggaagaacgaagtggtaaaaaa ctgaacgtcatcgacttcgaaggttcgaatccttctgctgtcaccagtcgacc-3′ gagatgcagtagctgaagcttccaagcttaggaagggacaggtggtcagctggagct-5′ (SEQ ID NO. 35)

Egs 5/5A (SEQ ID NO. 9)

SEQ ID NO. 8) 5′-tcgagtataacgtcatcgacttcgaaggttcgaatccttcaccggtcaccatttttttata catattgcagtagctgaagcttccaagcttaggaagtggccagtggtaaaaaaatat acgtcatcgacttcgaaggttcgaatccttcttcttacaccagtcgacc-3′ tgcagtagctgaagcttccaagcttaggaagaagaatgtggtcagctggagct-5′ (SEQ ID NO. 36)

Egs 6/6A (SEQ ID NO. 10)

(SEQ ID NO. 10) 5′-tcgagggctacgtcatcgacttcgaaggttcgaatccttcttgcttcaccatttttt cccgatgcagtagctgaatgcttccaagcttaggaagaacgaagtggtaaaaaa acgtcatcgacttcgaaggttcgaatccttcttcttacaccagtcgacc-3′ tgcagtagctgaagcttccaagcttaggaagatccgggtggtcagctgcgtacggagct-5′ (SEQ ID NO. 37)

The pH4DOZENEGS—vector may be used to both deliver and express the example EGS sequences to appropriate eukaryotic cells in a manner as described for ribozymes in reference examples 1, 2 and 3 whereby the use of a codon optimised gag/pol and env genes would prevent EGSs from targeting these genes during viral production. The inclusion of the EGS sequences into an HIV derived vector will not only allow expression of such sequences in the target cell but also packaging and transfer of such therapeutic sequences by the patient's own HIV. These example EGS sequences target HIV RNA for cleavage by RNAse P. This example is not limiting and other suitable EGS and derived sequences may also be used; be they expressed singularly, in multiples, from pol I pol II or pol III promoters and derivatives thereof and/or in combination with other HIV treatments. Other appropriate nucleotide sequences of interest (NOIs) may also be included in combination with EGSs if preferred.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

References

Bender et al., 1987, J Virol 61: 1639-1646.

Chesebro, B., K. Wehrly, and W. Maury. 1990. J Virol. 64:4553-7.

Cosset et al., 1995, J. Virol. 69: 7430-7436.

Foecking, M. K., and H. Hofstetter. 1986. Gene. 45:101-105.

Forster and Altman, 1990, Science 249: 783-786.

Gervaix, A., X. Li, G. Kraus, and F. Wong Staal. 199. J Virol. 71 :3048-53.

Goodchild, J., V. Kohli. 1991 . Arch Biochem Biophys Feb 1; 284(2):386-391.

Haas, J., E.-C. Park, and B. Seed. 1996. Current Biology. 6:315.

Kawa et al., 1998, RNA 4: 1397-1406.

Kim, V. N., K. Mitrophanous, S. M. Kingsman, and K. A. J. 1998. J Virol 72: 811-816.

Lever, A. M. 1995. Br Med Bull. 51:149-66.

Ma et al., 1998, Antisense and Nucleic Acid Drug Development 8: 415-426.

Ory, D. S., B. A. Neugeboren, and R. C. Mulligan. 1996. Proc Natl Acad Sci U S A. 93:11400-6.

Pear et al., 1993, Proc Natl Acad Sci 90: 8392-8396.

Riddell, S. R., M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D.

Lupton, R. W. Overell, T. C. Reynolds, L. Corey, and P. D. Greenberg. 1996. Nat Med. 2:216-23.

Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. Nucleic Acids Res. 23:628-33.

Spector, D. H., E. Wade, D. A. Wright, V. Koval, C. Clark, D. Jaquish, and S. A. Spector. 1990. J Virol. 64:2298-2308.

Srinivasakumar, N., N. Chazal, C. Helga Maria, S. Prasad, M. L. Hammarskjold, and D. Rekosh. 1997. J Virol. 71 :5841-8.

Valsesia Wittmann, S., A. Drynda, G. Deleage, M. Aumailiey, J. M. Heard, O. Danos, G.

Verdier, and F. L. Cosset 1994. J Virol. 68:4609-19.

Werner et al., 1997, Nucleic Acids Symposium Series No. 36: 19-21.

Werner et al., 1998, RNA 4: 847-855.

Yu, H., A. B. Rabson, M. Kaul, Y. Ron, and J. P. Dougherty. 1996. J Virol. 70:4530-37.

Yuan and Altman, 1994, Science 263:1269-1273.

Yuan and Altman, 1995, EMBO J. 14: 159-168.

Yuan et al., 1992, Proc Natl Acad Sci 89: 8006-8010.

Zhu, Z. H., S. S. Chen, and A. S. Huang. 1990. J Acquir Immune Defic Syndr. 3:215-9.

Zolotukhin, S., M. Potter, W. W. Hauswirth, J. Guy, and N. Muzyczka. 1996. J Virol. 70:4646-54.

73 1 4307 DNA Human immunodeficiency virus type 1 1atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgatggga aaaaattcgg 60ttaaggccag ggggaaagaa aaaatataaa ttaaaacata tagtatgggc aagcagggag 120ctagaacgat tcgcagttaa tcctggcctg ttagaaacat cagaaggctg tagacaaata 180ctgggacagc tacaaccatc ccttcagaca ggatcagaag aacttagatc attatataat 240acagtagcaa ccctctattg tgtgcatcaa aggatagaga taaaagacac caaggaagct 300ttagacaaga tagaggaaga gcaaaacaaa agtaagaaaa aagcacagca agcagcagct 360gacacaggac acagcaatca ggtcagccaa aattacccta tagtgcagaa catccagggg 420caaatggtac atcaggccat atcacctaga actttaaatg catgggtaaa agtagtagaa 480gagaaggctt tcagcccaga agtgataccc atgttttcag cattatcaga aggagccacc 540ccacaagatt taaacaccat gctaaacaca gtggggggac atcaagcagc catgcaaatg 600ttaaaagaga ccatcaatga ggaagctgca gaatgggata gagtgcatcc agtgcatgca 660gggcctattg caccaggcca gatgagagaa ccaaggggaa gtgacatagc aggaactact 720agtacccttc aggaacaaat aggatggatg acaaataatc cacctatccc agtaggagaa 780atttataaaa gatggataat cctgggatta aataaaatag taagaatgta tagccctacc 840agcattctgg acataagaca aggaccaaag gaacccttta gagactatgt agaccggttc 900tataaaactc taagagccga gcaagcttca caggaggtaa aaaattggat gacagaaacc 960ttgttggtcc aaaatgcgaa cccagattgt aagactattt taaaagcatt gggaccagcg 1020gctacactag aagaaatgat gacagcatgt cagggagtag gaggacccgg ccataaggca 1080agagttttgg ctgaagcaat gagccaagta acaaattcag ctaccataat gatgcagaga 1140ggcaatttta ggaaccaaag aaagattgtt aagtgtttca attgtggcaa agaagggcac 1200acagccagaa attgcagggc ccctaggaaa aagggctgtt ggaaatgtgg aaaggaagga 1260caccaaatga aagattgtac tgagagacag gctaattttt tagggaagat ctggccttcc 1320tacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa 1380gagagcttca ggtctggggt agagacaaca actccccctc agaagcagga gccgatagac 1440aaggaactgt atcctttaac ttccctcagg tcactctttg gcaacgaccc ctcgtcacaa 1500taaagatagg ggggcaacta aaggaagctc tattagatac aggagcagat gatacagtat 1560tagaagaaat gagtttgcca ggaagatgga aaccaaaaat gataggggga attggaggtt 1620ttatcaaagt aagacagtat gatcagatac tcatagaaat ctgtggacat aaagctatag 1680gtacagtatt agtaggacct acacctgtca acataattgg aagaaatctg ttgactcaga 1740ttggttgcac tttaaatttt cccattagcc ctattgagac tgtaccagta aaattaaagc 1800caggaatgga tggcccaaaa gttaaacaat ggccattgac agaagaaaaa ataaaagcat 1860tagtagaaat ttgtacagag atggaaaagg aagggaaaat ttcaaaaatt gggcctgaaa 1920atccatacaa tactccagta tttgccataa agaaaaaaga cagtactaaa tggagaaaat 1980tagtagattt cagagaactt aataagagaa ctcaagactt ctgggaagtt caattaggaa 2040taccacatcc cgcagggtta aaaaagaaaa aatcagtaac agtactggat gtgggtgatg 2100catatttttc agttccctta gatgaagact tcaggaagta tactgcattt accataccta 2160gtataaacaa tgagacacca gggattagat atcagtacaa tgtgcttcca cagggatgga 2220aaggatcacc agcaatattc caaagtagca tgacaaaaat cttagagcct tttagaaaac 2280aaaatccaga catagttatc tatcaataca tggatgattt gtatgtagga tctgacttag 2340aaatagggca gcatagaaca aaaatagagg agctgagaca acatctgttg aggtggggac 2400ttaccacacc agacaaaaaa catcagaaag aacctccatt cctttggatg ggttatgaac 2460tccatcctga taaatggaca gtacagccta tagtgctgcc agaaaaagac agctggactg 2520tcaatgacat acagaagtta gtggggaaat tgaattgggc aagtcagatt tacccaggga 2580ttaaagtaag gcaattatgt aaactcctta gaggaaccaa agcactaaca gaagtaatac 2640cactaacaga agaagcagag ctagaactgg cagaaaacag agagattcta aaagaaccag 2700tacatggagt gtattatgac ccatcaaaag acttaatagc agaaatacag aagcaggggc 2760aaggccaatg gacatatcaa atttatcaag agccatttaa aaatctgaaa acaggaaaat 2820atgcaagaat gaggggtgcc cacactaatg atgtaaaaca attaacagag gcagtgcaaa 2880aaataaccac agaaagcata gtaatatggg gaaagactcc taaatttaaa ctgcccatac 2940aaaaggaaac atgggaaaca tggtggacag agtattggca agccacctgg attcctgagt 3000gggagtttgt taatacccct cccttagtga aattatggta ccagttagag aaagaaccca 3060tagtaggagc agaaaccttc tatgtagatg gggcagctaa cagggagact aaattaggaa 3120aagcaggata tgttactaat agaggaagac aaaaagttgt caccctaact gacacaacaa 3180atcagaagac tgagttacaa gcaatttatc tagctttgca ggattcggga ttagaagtaa 3240acatagtaac agactcacaa tatgcattag gaatcattca agcacaacca gatcaaagtg 3300aatcagagtt agtcaatcaa ataatagagc agttaataaa aaaggaaaag gtctatctgg 3360catgggtacc agcacacaaa ggaattggag gaaatgaaca agtagataaa ttagtcagtg 3420ctggaatcag gaaagtacta tttttagatg gaatagataa ggcccaagat gaacatgaga 3480aatatcacag taattggaga gcaatggcta gtgattttaa cctgccacct gtagtagcaa 3540aagaaatagt agccagctgt gataaatgtc agctaaaagg agaagccatg catggacaag 3600tagactgtag tccaggaata tggcaactag attgtacaca tttagaagga aaagttatcc 3660tggtagcagt tcatgtagcc agtggatata tagaagcaga agttattcca gcagaaacag 3720ggcaggaaac agcatatttt cttttaaaat tagcaggaag atggccagta aaaacaatac 3780atactgacaa tggcagcaat ttcaccggtg ctacggttag ggccgcctgt tggtgggcgg 3840gaatcaagca ggaatttgga attccctaca atccccaaag tcaaggagta gtagaatcta 3900tgaataaaga attaaagaaa attataggac aggtaagaga tcaggctgaa catcttaaga 3960cagcagtaca aatggcagta ttcatccaca attttaaaag aaaagggggg attggggggt 4020acagtgcagg ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac 4080aaaaacaaat tacaaaaatt caaaattttc gggtttatta cagggacagc agaaattcac 4140tttggaaagg accagcaaag ctcctctgga aaggtgaagg ggcagtagta atacaagata 4200atagtgacat aaaagtagtg ccaagaagaa aagcaaagat cattagggat tatggaaaac 4260agatggcagg tgatgattgt gtggcaagta gacaggatga ggattag 4307 2 4307 DNA Artificial Sequence Description of Artificial Sequence gagpol-SYNgp-codon optimised gagpol sequence 2atgggcgccc gcgccagcgt gctgtcgggc ggcgagctgg accgctggga gaagatccgc 60ctgcgccccg gcggcaaaaa gaagtacaag ctgaagcaca tcgtgtgggc cagccgcgaa 120ctggagcgct tcgccgtgaa ccccgggctc ctggagacca gcgaggggtg ccgccagatc 180ctcggccaac tgcagcccag cctgcaaacc ggcagcgagg agctgcgcag cctgtacaac 240accgtggcca cgctgtactg cgtccaccag cgcatcgaaa tcaaggatac gaaagaggcc 300ctggataaaa tcgaagagga acagaataag agcaaaaaga aggcccaaca ggccgccgcg 360gacaccggac acagcaacca ggtcagccag aactacccca tcgtgcagaa catccagggg 420cagatggtgc accaggccat ctccccccgc acgctgaacg cctgggtgaa ggtggtggaa 480gagaaggctt ttagcccgga ggtgataccc atgttctcag ccctgtcaga gggagccacc 540ccccaagatc tgaacaccat gctcaacaca gtggggggac accaggccgc catgcagatg 600ctgaaggaga ccatcaatga ggaggctgcc gaatgggatc gtgtgcatcc ggtgcacgca 660gggcccatcg caccgggcca gatgcgtgag ccacggggct cagacatcgc cggaacgact 720agtacccttc aggaacagat cggctggatg accaacaacc cacccatccc ggtgggagaa 780atctacaaac gctggatcat cctgggcctg aacaagatcg tgcgcatgta tagccctacc 840agcatcctgg acatccgcca aggcccgaag gaaccctttc gcgactacgt ggaccggttc 900tacaaaacgc tccgcgccga gcaggctagc caggaggtga agaactggat gaccgaaacc 960ctgctggtcc agaacgcgaa cccggactgc aagacgatcc tgaaggccct gggcccagcg 1020gctaccctag aggaaatgat gaccgcctgt cagggagtgg gcggacccgg ccacaaggca 1080cgcgtcctgg ctgaggccat gagccaggtg accaactccg ctaccatcat gatgcagcgc 1140ggcaactttc ggaaccaacg caagatcgtc aagtgcttca actgtggcaa agaagggcac 1200acagcccgca actgcagggc ccctaggaaa aagggctgct ggaaatgcgg caaggaaggc 1260caccagatga aagactgtac tgagagacag gctaattttt tagggaagat ctggccttcc 1320tacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa 1380gagagcttca ggtctggggt agagacaaca actccccctc agaagcagga gccgatagac 1440aaggaactgt atcctttaac ttccctcaga tcactctttg gcaacgaccc ctcgtcacaa 1500taaagatagg ggggcagctc aaggaggctc tcctggacac cggagcagac gacaccgtgc 1560tggaggagat gtcgttgcca ggccgctgga agccgaagat gatcggggga atcggcggtt 1620tcatcaaggt gcgccagtat gaccagatcc tcatcgaaat ctgcggccac aaggctatcg 1680gtaccgtgct ggtgggcccc acacccgtca acatcatcgg acgcaacctg ttgacgcaga 1740tcggttgcac gctgaacttc cccattagcc ctatcgagac ggtaccggtg aagctgaagc 1800ccgggatgga cggcccgaag gtcaagcaat ggccattgac agaggagaag atcaaggcac 1860tggtggagat ttgcacagag atggaaaagg aagggaaaat ctccaagatt gggcctgaga 1920acccgtacaa cacgccggtg ttcgcaatca agaagaagga ctcgacgaaa tggcgcaagc 1980tggtggactt ccgcgagctg aacaagcgca cgcaagactt ctgggaggtt cagctgggca 2040tcccgcaccc cgcagggctg aagaagaaga aatccgtgac cgtactggat gtgggtgatg 2100cctacttctc cgttcccctg gacgaagact tcaggaagta cactgccttc acaatccctt 2160cgatcaacaa cgagacaccg gggattcgat atcagtacaa cgtgctgccc cagggctgga 2220aaggctctcc cgcaatcttc cagagtagca tgaccaaaat cctggagcct ttccgcaaac 2280agaaccccga catcgtcatc tatcagtaca tggatgactt gtacgtgggc tctgatctag 2340agatagggca gcaccgcacc aagatcgagg agctgcgcca gcacctgttg aggtggggac 2400tgaccacacc cgacaagaag caccagaagg agcctccctt cctctggatg ggttacgagc 2460tgcaccctga caaatggacc gtgcagccta tcgtgctgcc agagaaagac agctggactg 2520tcaacgacat acagaagctg gtggggaagt tgaactgggc cagtcagatt tacccaggga 2580ttaaggtgag gcagctgtgc aaactcctcc gcggaaccaa ggcactcaca gaggtgatcc 2640ccctaaccga ggaggccgag ctcgaactgg cagaaaaccg agagatccta aaggagcccg 2700tgcacggcgt gtactatgac ccctccaagg acctgatcgc cgagatccag aagcaggggc 2760aaggccagtg gacctatcag atttaccagg agcccttcaa gaacctgaag accggcaagt 2820acgcccggat gaggggtgcc cacactaacg acgtcaagca gctgaccgag gccgtgcaga 2880agatcaccac cgaaagcatc gtgatctggg gaaagactcc taagttcaag ctgcccatcc 2940agaaggaaac ctgggaaacc tggtggacag agtattggca ggccacctgg attcctgagt 3000gggagttcgt caacacccct cccctggtga agctgtggta ccagctggag aaggagccca 3060tagtgggcgc cgaaaccttc tacgtggatg gggccgctaa cagggagact aagctgggca 3120aagccggata cgtcactaac cggggcagac agaaggttgt caccctcact gacaccacca 3180accagaagac tgagctgcag gccatttacc tcgctttgca ggactcgggc ctggaggtga 3240acatcgtgac agactctcag tatgccctgg gcatcattca agcccagcca gaccagagtg 3300agtccgagct ggtcaatcag atcatcgagc agctgatcaa gaaggaaaag gtctatctgg 3360cctgggtacc cgcccacaaa ggcattggcg gcaatgagca ggtcgacaag ctggtctcgg 3420ctggcatcag gaaggtgcta ttcctggatg gcatcgacaa ggcccaggac gagcacgaga 3480aataccacag caactggcgg gccatggcta gcgacttcaa cctgccccct gtggtggcca 3540aagagatcgt ggccagctgt gacaagtgtc agctcaaggg cgaagccatg catggccagg 3600tggactgtag ccccggcatc tggcaactcg attgcaccca tctggagggc aaggttatcc 3660tggtagccgt ccatgtggcc agtggctaca tcgaggccga ggtcattccc gccgaaacag 3720ggcaggagac agcctacttc ctcctgaagc tggcaggccg gtggccagtg aagaccatcc 3780atactgacaa tggcagcaat ttcaccagtg ctacggttaa ggccgcctgc tggtgggcgg 3840gaatcaagca ggagttcggg atcccctaca atccccagag tcagggcgtc gtcgagtcta 3900tgaataagga gttaaagaag attatcggcc aggtcagaga tcaggctgag catctcaaga 3960ccgcggtcca aatggcggta ttcatccaca atttcaagcg gaaggggggg attggggggt 4020acagtgcggg ggagcggatc gtggacatca tcgcgaccga catccagact aaggagctgc 4080aaaagcagat taccaagatt cagaatttcc gggtctacta cagggacagc agaaatcccc 4140tctggaaagg cccagcgaag ctcctctgga agggtgaggg ggcagtagtg atccaggata 4200atagcgacat caaggtggtg cccagaagaa aggcgaagat cattagggat tatggcaaac 4260agatggcggg tgatgattgc gtggcgagca gacaggatga ggattag 4307 3 2571 DNA Human immunodeficiency virus type 1 3atgagagtga aggggatcag gaggaattat cagcactggt ggggatgggg cacgatgctc 60cttgggttat taatgatctg tagtgctaca gaaaaattgt gggtcacagt ctattatggg 120gtacctgtgt ggaaagaagc aaccaccact ctattttgtg catcagatgc taaagcatat 180gatacagagg tacataatgt ttgggccaca caagcctgtg tacccacaga ccccaaccca 240caagaagtag aattggtaaa tgtgacagaa aattttaaca tgtggaaaaa taacatggta 300gaacagatgc atgaggatat aatcagttta tgggatcaaa gcctaaagcc atgtgtaaaa 360ttaaccccac tctgtgttac tttaaattgc actgatttga ggaatactac taataccaat 420aatagtactg ctaataacaa tagtaatagc gagggaacaa taaagggagg agaaatgaaa 480aactgctctt tcaatatcac cacaagcata agagataaga tgcagaaaga atatgcactt 540ctttataaac ttgatatagt atcaatagat aatgatagta ccagctatag gttgataagt 600tgtaatacct cagtcattac acaagcttgt ccaaagatat cctttgagcc aattcccata 660cactattgtg ccccggctgg ttttgcgatt ctaaaatgta acgataaaaa gttcagtgga 720aaaggatcat gtaaaaatgt cagcacagta caatgtacac atggaattag gccagtagta 780tcaactcaac tgctgttaaa tggcagtcta gcagaagaag aggtagtaat tagatctgag 840aatttcactg ataatgctaa aaccatcata gtacatctga atgaatctgt acaaattaat 900tgtacaagac ccaactacaa taaaagaaaa aggatacata taggaccagg gagagcattt 960tatacaacaa aaaatataat aggaactata agacaagcac attgtaacat tagtagagca 1020aaatggaatg acactttaag acagatagtt agcaaattaa aagaacaatt taagaataaa 1080acaatagtct ttaatcaatc ctcaggaggg gacccagaaa ttgtaatgca cagttttaat 1140tgtggagggg aatttttcta ctgtaataca tcaccactgt ttaatagtac ttggaatggt 1200aataatactt ggaataatac tacagggtca aataacaata tcacacttca atgcaaaata 1260aaacaaatta taaacatgtg gcaggaagta ggaaaagcaa tgtatgcccc tcccattgaa 1320ggacaaatta gatgttcatc aaatattaca gggctactat taacaagaga tggtggtaag 1380gacacggaca cgaacgacac cgagatcttc agacctggag gaggagatat gagggacaat 1440tggagaagtg aattatataa atataaagta gtaacaattg aaccattagg agtagcaccc 1500accaaggcaa agagaagagt ggtgcagaga gaaaaaagag cagcgatagg agctctgttc 1560cttgggttct taggagcagc aggaagcact atgggcgcag cgtcagtgac gctgacggta 1620caggccagac tattattgtc tggtatagtg caacagcaga acaatttgct gagggccatt 1680gaggcgcaac agcatatgtt gcaactcaca gtctggggca tcaagcagct ccaggcaaga 1740gtcctggctg tggaaagata cctaaaggat caacagctcc tggggttttg gggttgctct 1800ggaaaactca tttgcaccac tactgtgcct tggaatgcta gttggagtaa taaatctctg 1860gatgatattt ggaataacat gacctggatg cagtgggaaa gagaaattga caattacaca 1920agcttaatat actcattact agaaaaatcg caaacccaac aagaaaagaa tgaacaagaa 1980ttattggaat tggataaatg ggcaagtttg tggaattggt ttgacataac aaattggctg 2040tggtatataa aaatattcat aatgatagta ggaggcttgg taggtttaag aatagttttt 2100gctgtacttt ctatagtgaa tagagttagg cagggatact caccattgtc gttgcagacc 2160cgccccccag ttccgagggg acccgacagg cccgaaggaa tcgaagaaga aggtggagag 2220agagacagag acacatccgg tcgattagtg catggattct tagcaattat ctgggtcgac 2280ctgcggagcc tgttcctctt cagctaccac cacagagact tactcttgat tgcagcgagg 2340attgtggaac ttctgggacg cagggggtgg gaagtcctca aatattggtg gaatctccta 2400cagtattgga gtcaggaact aaagagtagt gctgttagct tgcttaatgc cacagctata 2460gcagtagctg aggggacaga tagggttata gaagtactgc aaagagctgg tagagctatt 2520ctccacatac ctacaagaat aagacagggc ttggaaaggg ctttgctata a 2571 4 2571 DNA Artificial Sequence Description of Artificial Sequence SYNgp-160mn-codon optimised env sequence 4atgagggtga aggggatccg ccgcaactac cagcactggt ggggctgggg cacgatgctc 60ctggggctgc tgatgatctg cagcgccacc gagaagctgt gggtgaccgt gtactacggc 120gtgcccgtgt ggaaggaggc caccaccacc ctgttctgcg ccagcgacgc caaggcgtac 180gacaccgagg tgcacaacgt gtgggccacc caggcgtgcg tgcccaccga ccccaacccc 240caggaggtgg agctcgtgaa cgtgaccgag aacttcaaca tgtggaagaa caacatggtg 300gagcagatgc atgaggacat catcagcctg tgggaccaga gcctgaagcc ctgcgtgaag 360ctgacccccc tgtgcgtgac cctgaactgc accgacctga ggaacaccac caacaccaac 420aacagcaccg ccaacaacaa cagcaacagc gagggcacca tcaagggcgg cgagatgaag 480aactgcagct tcaacatcac caccagcatc cgcgacaaga tgcagaagga gtacgccctg 540ctgtacaagc tggatatcgt gagcatcgac aacgacagca ccagctaccg cctgatctcc 600tgcaacacca gcgtgatcac ccaggcctgc cccaagatca gcttcgagcc catccccatc 660cactactgcg cccccgccgg cttcgccatc ctgaagtgca acgacaagaa gttcagcggc 720aagggcagct gcaagaacgt gagcaccgtg cagtgcaccc acggcatccg gccggtggtg 780agcacccagc tcctgctgaa cggcagcctg gccgaggagg aggtggtgat ccgcagcgag 840aacttcaccg acaacgccaa gaccatcatc gtgcacctga atgagagcgt gcagatcaac 900tgcacgcgtc ccaactacaa caagcgcaag cgcatccaca tcggccccgg gcgcgccttc 960tacaccacca agaacatcat cggcaccatc cgccaggccc actgcaacat ctctagagcc 1020aagtggaacg acaccctgcg ccagatcgtg agcaagctga aggagcagtt caagaacaag 1080accatcgtgt tcaaccagag cagcggcggc gaccccgaga tcgtgatgca cagcttcaac 1140tgcggcggcg aattcttcta ctgcaacacc agccccctgt tcaacagcac ctggaacggc 1200aacaacacct ggaacaacac caccggcagc aacaacaata ttaccctcca gtgcaagatc 1260aagcagatca tcaacatgtg gcaggaggtg ggcaaggcca tgtacgcccc ccccatcgag 1320ggccagatcc ggtgcagcag caacatcacc ggtctgctgc tgacccgcga cggcggcaag 1380gacaccgaca ccaacgacac cgaaatcttc cgccccggcg gcggcgacat gcgcgacaac 1440tggagatctg agctgtacaa gtacaaggtg gtgacgatcg agcccctggg cgtggccccc 1500accaaggcca agcgccgcgt ggtgcagcgc gagaagcggg ccgccatcgg cgccctgttc 1560ctgggcttcc tgggggcggc gggcagcacc atgggggccg ccagcgtgac cctgaccgtg 1620caggcccgcc tgctcctgag cggcatcgtg cagcagcaga acaacctcct ccgcgccatc 1680gaggcccagc agcatatgct ccagctcacc gtgtggggca tcaagcagct ccaggcccgc 1740gtgctggccg tggagcgcta cctgaaggac cagcagctcc tgggcttctg gggctgctcc 1800ggcaagctga tctgcaccac cacggtaccc tggaacgcct cctggagcaa caagagcctg 1860gacgacatct ggaacaacat gacctggatg cagtgggagc gcgagatcga taactacacc 1920agcctgatct acagcctgct ggagaagagc cagacccagc aggagaagaa cgagcaggag 1980ctgctggagc tggacaagtg ggcgagcctg tggaactggt tcgacatcac caactggctg 2040tggtacatca aaatcttcat catgattgtg ggcggcctgg tgggcctccg catcgtgttc 2100gccgtgctga gcatcgtgaa ccgcgtgcgc cagggctaca gccccctgag cctccagacc 2160cggccccccg tgccgcgcgg gcccgaccgc cccgagggca tcgaggagga gggcggcgag 2220cgcgaccgcg acaccagcgg caggctcgtg cacggcttcc tggcgatcat ctgggtcgac 2280ctccgcagcc tgttcctgtt cagctaccac caccgcgacc tgctgctgat cgccgcccgc 2340atcgtggaac tcctaggccg ccgcggctgg gaggtgctga agtactggtg gaacctcctc 2400cagtattgga gccaggagct gaagtccagc gccgtgagcc tgctgaacgc caccgccatc 2460gccgtggccg agggcaccga ccgcgtgatc gaggtgctcc agagggccgg gagggcgatc 2520ctgcacatcc ccacccgcat ccgccagggg ctcgagaggg cgctgctgta a 2571 5 116 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 5tcgagcccgg ggatgacgtc atcgacttcg aaggttcgaa tccttctact gccaccattt 60tttctctacg tcatcgactt cgaaggttcg aatccttccc tgtccaccag tcgacc 116 6 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 6tcgagtatta cgtcatcgac ttcgaaggtt cgaatccttc tagattcacc attttttagg 60aacgtcatcg acttcgaagg ttcgaatcct tccagttcca ccagtcgacc 110 7 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 7tcgaggccaa cgtcatcgac ttcgaaggtt cgaatccttc tcttcccacc attttttttc 60cacgtcatcg acttcgaagg ttcgaatcct tcggggccca ccagtcgacc 110 8 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 8tcgagggcta cgtcatcgac ttcgaaggtt cgaatccttc ttgcttcacc attttttctg 60aacgtcatcg acttcgaagg ttcgaatcct tctgctgtca ccagtcgacc 110 9 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 9tcgagtataa cgtcatcgac ttcgaaggtt cgaatccttc accggtcacc atttttttat 60aacgtcatcg acttcgaagg ttcgaatcct tcttcttaca ccagtcgacc 110 10 116 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 10tcgaggtaca cgtcatcgac ttcgaaggtt cgaatccttc gtagttcacc attttttgtg 60cacgtcatcg acttcgaagg ttcgaatcct tctaggccca ccagtcgacg catgcc 116 11 8560 DNA Artificial Sequence Description of Artificial Sequence Synthetic nucleotide pH4DOZENEGS sequence 11ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 60ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg 120ccacgttcgc cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat 180ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg 240ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 300gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt 360tataagggat tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat 420ttaacgcgaa ttttaacaaa atattaacgc ttacaatttc cattcgccat tcaggctgcg 480caactgttgg gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg 540gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt cacgacgttg 600taaaacgacg gccagtgagc gcgcgtaata cgactcacta tagggcgaat tggagctcca 660ccgcggtggc ggccgctcta gagtccgtta cataacttac ggtaaatggc ccgcctggct 720gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc atagtaacgc 780caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact gcccacttgg 840cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat gacggtaaat 900ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact tggcagtaca 960tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac atcaatgggc 1020gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac gtcaatggga 1080gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac tccgccccat 1140tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga gctcgtttag 1200tgaaccggtc tctctggtta gaccagatct gagcctggga gctctctggc taactaggga 1260acccactgct taagcctcaa taaagcttgc cttgagtgct tcaagtagtg tgtgcccgtc 1320tgttgtgtga ctctggtaac tagagatccc tcagaccctt ttagtcagtg tggaaaatct 1380ctagcagtgg cgcccgaaca gggacttgaa agcgaaaggg aaaccagagg agctctctcg 1440acgcaggact cggcttgctg aagcgcgcac ggcaagaggc gaggggcggc gactggtgag 1500tacgccaaaa attttgacta gcggaggcta gaaggagaga gatgggtgcg agagcgtcag 1560tattaagcgg gggagaatta gatcgcgatg ggaaaaaatt cggttaaggc cagggggaaa 1620gaaaaaatat aaattaaaac atatagtatg ggcaagcagg gagctagaac gattcgcagt 1680taatcctggc ctgttagaaa catcagaagg ctgtagacaa atactgggac agctacaacc 1740atcccttcag acaggatcag aagaacttag atcattatat aatacagtag caaccctcta 1800ttgtgtgcat caaaggttga gataaaagac accaaggaag ctttagacaa gatagaggga 1860gagcaaaaca aaagtaagaa aaaagcacag caagcagcag ctgacacagg acacagcaat 1920caggtcagcc aaaattaccc tatagtgcag aacatccagg ggcaaatggt acatcaggcc 1980atatcaccta gaactttaaa tgcatgggta aaagtagtag aagagaaggc tttcagccca 2040gaagtgatac ccatgttttc agcattatca gaaggagcca ccccacaaga tttaaacacc 2100atgctaaaca cagtgggggg acatcaagca gccatgcaaa tgttaaaaga gaccatcaat 2160gaggaagctg caggaattcg cctaaaactg cttgtaccaa ttgctattgt aaaaagtgtt 2220gctttcattg ccaagtttgt ttcataacaa aagccttagg catctcctat ggcaggaaga 2280agcggagaca gcgacgaaga gctcatcaga acagtcagac tcatcaagct tctctatcaa 2340agcagtaagt agtacatgta acgcaaccta taccaatagt agcaatagta gcattagtag 2400tagcaataat aatagcaata gttgtgtggt ccatagtaat catagaatat aggaaaatat 2460taagacaaag aaaaatagac aggttaattg atagactaat agaaagagca gaagacagtg 2520gcaatgagag tgaaggagaa atatcagcac ttgtggagat gggggtggag atggggcacc 2580atgctccttg ggatgttgat gatctgtagt gctacagaaa aattgtgggt cacagtctat 2640tatggggtac ctgtgtggaa ggaagcaacc accactctat tttgtgcatc agatgctaaa 2700gcatagatct tcagacttgg aggaggagat atgagggaca attggagaag tgaattatat 2760aaatataaag tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc aaagagaaga 2820gtggtgcaga gagaaaaaag agcagtggga ataggagctt tgttccttgg gttcttggga 2880gcagcaggaa gcactatggg cgcagcgtca atgacgctga cggtacaggc cagacaatta 2940ttgtctggta tagtgcagca gcagaacaat ttgctgaggg ctattgaggc gcaacagcat 3000ctgttgcaac tcacagtctg gggcatcaag cagctccagg caagaatcct ggctgtggaa 3060agatacctaa aggatcaaca gctcctgggg atttggggtt gctctggaaa actcatttgc 3120accactgctg tgccttggaa tgctagttgg agtaataaat ctctggaaca gatctggaat 3180cacacgacct ggatggagtg ggacagagaa attaacaatt acacaagctt aatacactcc 3240ttaattgaag aatcgcaaaa ccagcaagaa aagaatgaac aagaattatt ggaattagat 3300aaatgggcaa gtttgtggaa ttggtttaac ataacaaatt ggctgtggta tataaaatta 3360ttcataatga tagtaggagg cttggtaggt ttaagaatag tttttgctgt actttctata 3420gtgaatagag ttaggcaggg atattcacca ttatcgtttc agacccacct cccaaccccg 3480aggggacccg acaggcccga aggaatagaa gaagaaggtg gagagagaga cagagacaga 3540tccattcgat tagtgaacgg atccttggca cttatctggg acgatctgcg gagcctgtgc 3600ctcttcagct accaccgctt gagagactta ctcttgattg taacgaggat tgtggaactt 3660ctgggacgca gggggtggga agccctcaaa tattggtgga atctcctaca gtattggagt 3720caggaactaa agaatagtgc tgttagcttg ctcaatgcca cagccatagc agtagctgag 3780gggacagata gggttataga agtagtacaa ggagcttgta gagctattcg ccacatacct 3840agaagaataa gacagggctt ggaaaggatt ttgctataag atgggtggca agtggtcaaa 3900aagtagtgtg attggatggc ctactgtaag ggaaagaatg agacgagctg agccagcagc 3960agatagggtg ggagcagcat ctcgacgctg caggagtggg gaggcacgat ggccgctttg 4020gtcgaggcgg atccggccat tagccatatt attcattggt tatatagcat aaatcaatat 4080tggctattgg ccattgcata cgttgtatcc atatcataat atgtacattt atattggctc 4140atgtccaaca ttaccgccat gttgacattg attattgact agttattaat agtaatcaat 4200tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac ttacggtaaa 4260tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt 4320tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt atttacggta 4380aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc ctattgacgt 4440caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat gggactttcc 4500tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc ggttttggca 4560gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc tccaccccat 4620tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa aatgtcgtaa 4680caactccgcc ccattgacgc aaatgggcgg taggcatgta cggtgggagg tctatataag 4740cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc catccacgct gttttgacct 4800ccatagaaga caccgggacc gatccagcct ccgcggcccc aagcttcagc tgctcgagcc 4860cggggatgac gtcatcgact tcgaaggttc gaatccttct actgccacca ttttttctct 4920acgtcatcga cttcgaaggt tcgaatcctt ccctgtccac cagtcgagta ttacgtcatc 4980gacttcgaag gttcgaatcc ttctagattc accatttttt aggaacgtca tcgacttcga 5040aggttcgaat ccttccagtt ccaccagtcg aggccaacgt catcgacttc gaaggttcga 5100atccttctct tcccaccatt ttttttccac gtcatcgact tcgaaggttc gaatccttcg 5160gggcccacca gtcgagggct acgtcatcga cttcgaaggt tcgaatcctt cttgcttcac 5220cattttttct gaacgtcatc gacttcgaag gttcgaatcc ttctgctgtc accagtcgag 5280tataacgtca tcgacttcga aggttcgaat ccttcaccgg tcaccatttt tttataacgt 5340catcgacttc gaaggttcga atccttcttc ttacaccagt cgaggtacac gtcatcgact 5400tcgaaggttc gaatccttcg tagttcacca ttttttgtgc acgtcatcga cttcgaaggt 5460tcgaatcctt ctaggcccac cagtcgacgc atgcctgcag gtcgaggtcg ataccgtcga 5520gacctagaaa aacatggagc aatcacaagt agcaatacag cagctaccaa tgctgattgt 5580gcctggctag aagcacaaga ggaggaggag gtgggttttc cagtcacacc tcaggtacct 5640ttaagaccaa tgacttacaa ggcagctgta gatcttagcc actttttaaa agaaaagggg 5700ggactggaag ggctaattca ctcccaacga agacaagata tccttgatct gtggatctac 5760cacacacaag gctacttccc tgattggcag aactacacac cagggccagg gatcagatat 5820ccactgacct ttggatggtg ctacaagcta gtaccagttg agcaagagaa ggtagaagaa 5880gccaatgaag gagagaacac ccgcttgtta caccctgtga gcctgcatgg gatggatgac 5940ccggagagag aagtattaga gtggaggttt gacagccgcc tagcatttca tcacatggcc 6000cgagagctgc atccggagta cttcaagaac tgctgacatc gagcttgcta caagggactt 6060tccgctgggg actttccagg gaggcgtggc ctgggcggga ctggggagtg gcgagccctc 6120agatgctgca tataagcagc tgctttttgc ctgtactggg tctctctggt tagaccagat 6180ctgagcctgg gagctctctg gctaactagg gaacccactg cttaagcctc aataaagctt 6240gccttgagtg cttcaagtag tgtgtgcccg tctgttgtgt gactctggta actagagatc 6300cctcagaccc ttttagtcag tgtggaaaat ctctagcagt cgaggggggg cccggtaccc 6360agcttttgtt ccctttagtg agggttaatt gcgcgcttgg cgtaatcatg gtcatagctg 6420tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc cggaagcata 6480aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc gttgcgctca 6540ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc 6600gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg 6660cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta 6720tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc 6780aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag 6840catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac 6900caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc 6960ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt 7020aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc 7080gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga 7140cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta 7200ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta 7260tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga 7320tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg 7380cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag 7440tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc 7500tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact 7560tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt 7620cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta 7680ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta 7740tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc 7800gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat 7860agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt 7920atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg 7980tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca 8040gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta 8100agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg 8160cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact 8220ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg 8280ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt 8340actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga 8400ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc 8460atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa 8520caaatagggg ttccgcgcac atttccccga aaagtgccac 8560 12 4642 DNA Artificial Sequence Description of Artificial Sequence pSYNGP2- codon optimised HIV-1 gagpol with leader sequence 12gggtctctct ggttagacca gatctgagcc tgggagctct ctggctaact agggaaccca 60ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc ccgtctgttg 120tgtgactctg gtaactagag atccctcaga cccttttagt cagtgtggaa aatctctagc 180agtggcgccc gaacagggac ctgaaagcga aagggaaacc agagctctct cgacgcagga 240ctcggcttgc tgaagcgccc gcacggcaag aggcgagggg cggcgactgg tgagtacgcc 300aaaaattttg actagcggag gctagaagga gagagatggg cgcccgcgcc agcgtgctgt 360cgggcggcga gctggaccgc tgggagaaga tccgcctgcg ccccggcggc aaaaagaagt 420acaagctgaa gcacatcgtg tgggccagcc gcgaactgga gcgcttcgcc gtgaaccccg 480ggctcctgga gaccagcgag gggtgccgcc agatcctcgg ccaactgcag cccagcctgc 540aaaccggcag cgaggagctg cgcagcctgt acaacaccgt ggccacgctg tactgcgtcc 600accagcgcat cgaaatcaag gatacgaaag aggccctgga taaaatcgaa gaggaacaga 660ataagagcaa aaagaaggcc caacaggccg ccgcggacac cggacacagc aaccaggtca 720gccagaacta ccccatcgtg cagaacatcc aggggcagat ggtgcaccag gccatctccc 780cccgcacgct gaacgcctgg gtgaaggtgg tggaagagaa ggcttttagc ccggaggtga 840tacccatgtt ctcagccctg tcagagggag ccacccccca agatctgaac accatgctca 900acacagtggg gggacaccag gccgccatgc agatgctgaa ggagaccatc aatgaggagg 960ctgccgaatg ggatcgtgtg catccggtgc acgcagggcc catcgcaccg ggccagatgc 1020gtgagccacg gggctcagac atcgccggaa cgactagtac ccttcaggaa cagatcggct 1080ggatgaccaa caacccaccc atcccggtgg gagaaatcta caaacgctgg atcatcctgg 1140gcctgaacaa gatcgtgcgc atgtatagcc ctaccagcat cctggacatc cgccaaggcc 1200cgaaggaacc ctttcgcgac tacgtggacc ggttctacaa aacgctccgc gccgagcagg 1260ctagccagga ggtgaagaac tggatgaccg aaaccctgct ggtccagaac gcgaacccgg 1320actgcaagac gatcctgaag gccctgggcc cagcggctac cctagaggaa atgatgaccg 1380cctgtcaggg agtgggcgga cccggccaca aggcacgcgt cctggctgag gccatgagcc 1440aggtgaccaa ctccgctacc atcatgatgc agcgcggcaa ctttcggaac caacgcaaga 1500tcgtcaagtg cttcaactgt ggcaaagaag ggcacacagc ccgcaactgc agggccccta 1560ggaaaaaggg ctgttggaaa tgtggaaagg aaggacacca aatgaaagat tgtactgaga 1620gacaggctaa ttttttaggg aagatctggc cttcccacaa gggaaggcca gggaattttc 1680ttcagagcag accagagcca acagccccac cagaagagag cttcaggttt ggggaagaga 1740caacaactcc ctctcagaag caggagccga tagacaagga actgtatcct ttagcttccc 1800tcagatcact ctttggcagc gacccctcgt cacaataaag ataggggggc agctcaagga 1860ggctctcctg gacaccggag cagacgacac cgtgctggag gagatgtcgt tgccaggccg 1920ctggaagccg aagatgatcg ggggaatcgg cggtttcatc aaggtgcgcc agtatgacca 1980gatcctcatc gaaatctgcg gccacaaggc tatcggtacc gtgctggtgg gccccacacc 2040cgtcaacatc atcggacgca acctgttgac gcagatcggt tgcacgctga acttccccat 2100tagccctatc gagacggtac cggtgaagct gaagcccggg atggacggcc cgaaggtcaa 2160gcaatggcca ttgacagagg agaagatcaa ggcactggtg gagatttgca cagagatgga 2220aaaggaaggg aaaatctcca agattgggcc tgagaacccg tacaacacgc cggtgttcgc 2280aatcaagaag aaggactcga cgaaatggcg caagctggtg gacttccgcg agctgaacaa 2340gcgcacgcaa gacttctggg aggttcagct gggcatcccg caccccgcag ggctgaagaa 2400gaagaaatcc gtgaccgtac tggatgtggg tgatgcctac ttctccgttc ccctggacga 2460agacttcagg aagtacactg ccttcacaat cccttcgatc aacaacgaga caccggggat 2520tcgatatcag tacaacgtgc tgccccaggg ctggaaaggc tctcccgcaa tcttccagag 2580tagcatgacc aaaatcctgg agcctttccg caaacagaac cccgacatcg tcatctatca 2640gtacatggat gacttgtacg tgggctctga tctagagata gggcagcacc gcaccaagat 2700cgaggagctg cgccagcacc tgttgaggtg gggactgacc acacccgaca agaagcacca 2760gaaggagcct cccttcctct ggatgggtta cgagctgcac cctgacaaat ggaccgtgca 2820gcctatcgtg ctgccagaga aagacagctg gactgtcaac gacatacaga agctggtggg 2880gaagttgaac tgggccagtc agatttaccc agggattaag gtgaggcagc tgtgcaaact 2940cctccgcgga accaaggcac tcacagaggt gatcccccta accgaggagg ccgagctcga 3000actggcagaa aaccgagaga tcctaaagga gcccgtgcac ggcgtgtact atgacccctc 3060caaggacctg atcgccgaga tccagaagca ggggcaaggc cagtggacct atcagattta 3120ccaggagccc ttcaagaacc tgaagaccgg caagtacgcc cggatgaggg gtgcccacac 3180taacgacgtc aagcagctga ccgaggccgt gcagaagatc accaccgaaa gcatcgtgat 3240ctggggaaag actcctaagt tcaagctgcc catccagaag gaaacctggg aaacctggtg 3300gacagagtat tggcaggcca cctggattcc tgagtgggag ttcgtcaaca cccctcccct 3360ggtgaagctg tggtaccagc tggagaagga gcccatagtg ggcgccgaaa ccttctacgt 3420ggatggggcc gctaacaggg agactaagct gggcaaagcc ggatacgtca ctaaccgggg 3480cagacagaag gttgtcaccc tcactgacac caccaaccag aagactgagc tgcaggccat 3540ttacctcgct ttgcaggact cgggcctgga ggtgaacatc gtgacagact ctcagtatgc 3600cctgggcatc attcaagccc agccagacca gagtgagtcc gagctggtca atcagatcat 3660cgagcagctg atcaagaagg aaaaggtcta tctggcctgg gtacccgccc acaaaggcat 3720tggcggcaat gagcaggtcg acaagctggt ctcggctggc atcaggaagg tgctattcct 3780ggatggcatc gacaaggccc aggacgagca cgagaaatac cacagcaact ggcgggccat 3840ggctagcgac ttcaacctgc cccctgtggt ggccaaagag atcgtggcca gctgtgacaa 3900gtgtcagctc aagggcgaag ccatgcatgg ccaggtggac tgtagccccg gcatctggca 3960actcgattgc acccatctgg agggcaaggt tatcctggta gccgtccatg tggccagtgg 4020ctacatcgag gccgaggtca ttcccgccga aacagggcag gagacagcct acttcctcct 4080gaagctggca ggccggtggc cagtgaagac catccatact gacaatggca gcaatttcac 4140cagtgctacg gttaaggccg cctgctggtg ggcgggaatc aagcaggagt tcgggatccc 4200ctacaatccc cagagtcagg gcgtcgtcga gtctatgaat aaggagttaa agaagattat 4260cggccaggtc agagatcagg ctgagcatct caagaccgcg gtccaaatgg cggtattcat 4320ccacaatttc aagcggaagg gggggattgg ggggtacagt gcgggggagc ggatcgtgga 4380catcatcgcg accgacatcc agactaagga gctgcaaaag cagattacca agattcagaa 4440tttccgggtc tactacaggg acagcagaaa tcccctctgg aaaggcccag cgaagctcct 4500ctggaagggt gagggggcag tagtgatcca ggataatagc gacatcaagg tggtgcccag 4560aagaaaggcg aagatcatta gggattatgg caaacagatg gcgggtgatg attgcgtggc 4620gagcagacag gatgaggatt ag 4642 13 4353 DNA Artificial Sequence Description of Artificial Sequence pSYNGP3- codon optimised HIV-1 gagpol with leader sequence from the major splice donor 13gtgagtacgc caaaaatttt gactagcgga ggctagaagg agagagatgg gcgcccgcgc 60cagcgtgctg tcgggcggcg agctggaccg ctgggagaag atccgcctgc gccccggcgg 120caaaaagaag tacaagctga agcacatcgt gtgggccagc cgcgaactgg agcgcttcgc 180cgtgaacccc gggctcctgg agaccagcga ggggtgccgc cagatcctcg gccaactgca 240gcccagcctg caaaccggca gcgaggagct gcgcagcctg tacaacaccg tggccacgct 300gtactgcgtc caccagcgca tcgaaatcaa ggatacgaaa gaggccctgg ataaaatcga 360agaggaacag aataagagca aaaagaaggc ccaacaggcc gccgcggaca ccggacacag 420caaccaggtc agccagaact accccatcgt gcagaacatc caggggcaga tggtgcacca 480ggccatctcc ccccgcacgc tgaacgcctg ggtgaaggtg gtggaagaga aggcttttag 540cccggaggtg atacccatgt tctcagccct gtcagaggga gccacccccc aagatctgaa 600caccatgctc aacacagtgg ggggacacca ggccgccatg cagatgctga aggagaccat 660caatgaggag gctgccgaat gggatcgtgt gcatccggtg cacgcagggc ccatcgcacc 720gggccagatg cgtgagccac ggggctcaga catcgccgga acgactagta cccttcagga 780acagatcggc tggatgacca acaacccacc catcccggtg ggagaaatct acaaacgctg 840gatcatcctg ggcctgaaca agatcgtgcg catgtatagc cctaccagca tcctggacat 900ccgccaaggc ccgaaggaac cctttcgcga ctacgtggac cggttctaca aaacgctccg 960cgccgagcag gctagccagg aggtgaagaa ctggatgacc gaaaccctgc tggtccagaa 1020cgcgaacccg gactgcaaga cgatcctgaa ggccctgggc ccagcggcta ccctagagga 1080aatgatgacc gcctgtcagg gagtgggcgg acccggccac aaggcacgcg tcctggctga 1140ggccatgagc caggtgacca actccgctac catcatgatg cagcgcggca actttcggaa 1200ccaacgcaag atcgtcaagt gcttcaactg tggcaaagaa gggcacacag cccgcaactg 1260cagggcccct aggaaaaagg gctgttggaa atgtggaaag gaaggacacc aaatgaaaga 1320ttgtactgag agacaggcta attttttagg gaagatctgg ccttcccaca agggaaggcc 1380agggaatttt cttcagagca gaccagagcc aacagcccca ccagaagaga gcttcaggtt 1440tggggaagag acaacaactc cctctcagaa gcaggagccg atagacaagg aactgtatcc 1500tttagcttcc ctcagatcac tctttggcag cgacccctcg tcacaataaa gatagggggg 1560cagctcaagg aggctctcct ggacaccgga gcagacgaca ccgtgctgga ggagatgtcg 1620ttgccaggcc gctggaagcc gaagatgatc gggggaatcg gcggtttcat caaggtgcgc 1680cagtatgacc agatcctcat cgaaatctgc ggccacaagg ctatcggtac cgtgctggtg 1740ggccccacac ccgtcaacat catcggacgc aacctgttga cgcagatcgg ttgcacgctg 1800aacttcccca ttagccctat cgagacggta ccggtgaagc tgaagcccgg gatggacggc 1860ccgaaggtca agcaatggcc attgacagag gagaagatca aggcactggt ggagatttgc 1920acagagatgg aaaaggaagg gaaaatctcc aagattgggc ctgagaaccc gtacaacacg 1980ccggtgttcg caatcaagaa gaaggactcg acgaaatggc gcaagctggt ggacttccgc 2040gagctgaaca agcgcacgca agacttctgg gaggttcagc tgggcatccc gcaccccgca 2100gggctgaaga agaagaaatc cgtgaccgta ctggatgtgg gtgatgccta cttctccgtt 2160cccctggacg aagacttcag gaagtacact gccttcacaa tcccttcgat caacaacgag 2220acaccgggga ttcgatatca gtacaacgtg ctgccccagg gctggaaagg ctctcccgca 2280atcttccaga gtagcatgac caaaatcctg gagcctttcc gcaaacagaa ccccgacatc 2340gtcatctatc agtacatgga tgacttgtac gtgggctctg atctagagat agggcagcac 2400cgcaccaaga tcgaggagct gcgccagcac ctgttgaggt ggggactgac cacacccgac 2460aagaagcacc agaaggagcc tcccttcctc tggatgggtt acgagctgca ccctgacaaa 2520tggaccgtgc agcctatcgt gctgccagag aaagacagct ggactgtcaa cgacatacag 2580aagctggtgg ggaagttgaa ctgggccagt cagatttacc cagggattaa ggtgaggcag 2640ctgtgcaaac tcctccgcgg aaccaaggca ctcacagagg tgatccccct aaccgaggag 2700gccgagctcg aactggcaga aaaccgagag atcctaaagg agcccgtgca cggcgtgtac 2760tatgacccct ccaaggacct gatcgccgag atccagaagc aggggcaagg ccagtggacc 2820tatcagattt accaggagcc cttcaagaac ctgaagaccg gcaagtacgc ccggatgagg 2880ggtgcccaca ctaacgacgt caagcagctg accgaggccg tgcagaagat caccaccgaa 2940agcatcgtga tctggggaaa gactcctaag ttcaagctgc ccatccagaa ggaaacctgg 3000gaaacctggt ggacagagta ttggcaggcc acctggattc ctgagtggga gttcgtcaac 3060acccctcccc tggtgaagct gtggtaccag ctggagaagg agcccatagt gggcgccgaa 3120accttctacg tggatggggc cgctaacagg gagactaagc tgggcaaagc cggatacgtc 3180actaaccggg gcagacagaa ggttgtcacc ctcactgaca ccaccaacca gaagactgag 3240ctgcaggcca tttacctcgc tttgcaggac tcgggcctgg aggtgaacat cgtgacagac 3300tctcagtatg ccctgggcat cattcaagcc cagccagacc agagtgagtc cgagctggtc 3360aatcagatca tcgagcagct gatcaagaag gaaaaggtct atctggcctg ggtacccgcc 3420cacaaaggca ttggcggcaa tgagcaggtc gacaagctgg tctcggctgg catcaggaag 3480gtgctattcc tggatggcat cgacaaggcc caggacgagc acgagaaata ccacagcaac 3540tggcgggcca tggctagcga cttcaacctg ccccctgtgg tggccaaaga gatcgtggcc 3600agctgtgaca agtgtcagct caagggcgaa gccatgcatg gccaggtgga ctgtagcccc 3660ggcatctggc aactcgattg cacccatctg gagggcaagg ttatcctggt agccgtccat 3720gtggccagtg gctacatcga ggccgaggtc attcccgccg aaacagggca ggagacagcc 3780tacttcctcc tgaagctggc aggccggtgg ccagtgaaga ccatccatac tgacaatggc 3840agcaatttca ccagtgctac ggttaaggcc gcctgctggt gggcgggaat caagcaggag 3900ttcgggatcc cctacaatcc ccagagtcag ggcgtcgtcg agtctatgaa taaggagtta 3960aagaagatta tcggccaggt cagagatcag gctgagcatc tcaagaccgc ggtccaaatg 4020gcggtattca tccacaattt caagcggaag ggggggattg gggggtacag tgcgggggag 4080cggatcgtgg acatcatcgc gaccgacatc cagactaagg agctgcaaaa gcagattacc 4140aagattcaga atttccgggt ctactacagg gacagcagaa atcccctctg gaaaggccca 4200gcgaagctcc tctggaaggg tgagggggca gtagtgatcc aggataatag cgacatcaag 4260gtggtgccca gaagaaaggc gaagatcatt agggattatg gcaaacagat ggcgggtgat 4320gattgcgtgg cgagcagaca ggatgaggat tag 4353 14 4327 DNA Artificial Sequence Description of Artificial Sequence pSYNGP4- codon optimised HIV-1 gagpol with 20bp of the leader sequence of HIV-1 14cggaggctag aaggagagag atgggcgccc gcgccagcgt gctgtcgggc ggcgagctgg 60accgctggga gaagatccgc ctgcgccccg gcggcaaaaa gaagtacaag ctgaagcaca 120tcgtgtgggc cagccgcgaa ctggagcgct tcgccgtgaa ccccgggctc ctggagacca 180gcgaggggtg ccgccagatc ctcggccaac tgcagcccag cctgcaaacc ggcagcgagg 240agctgcgcag cctgtacaac accgtggcca cgctgtactg cgtccaccag cgcatcgaaa 300tcaaggatac gaaagaggcc ctggataaaa tcgaagagga acagaataag agcaaaaaga 360aggcccaaca ggccgccgcg gacaccggac acagcaacca ggtcagccag aactacccca 420tcgtgcagaa catccagggg cagatggtgc accaggccat ctccccccgc acgctgaacg 480cctgggtgaa ggtggtggaa gagaaggctt ttagcccgga ggtgataccc atgttctcag 540ccctgtcaga gggagccacc ccccaagatc tgaacaccat gctcaacaca gtggggggac 600accaggccgc catgcagatg ctgaaggaga ccatcaatga ggaggctgcc gaatgggatc 660gtgtgcatcc ggtgcacgca gggcccatcg caccgggcca gatgcgtgag ccacggggct 720cagacatcgc cggaacgact agtacccttc aggaacagat cggctggatg accaacaacc 780cacccatccc ggtgggagaa atctacaaac gctggatcat cctgggcctg aacaagatcg 840tgcgcatgta tagccctacc agcatcctgg acatccgcca aggcccgaag gaaccctttc 900gcgactacgt ggaccggttc tacaaaacgc tccgcgccga gcaggctagc caggaggtga 960agaactggat gaccgaaacc ctgctggtcc agaacgcgaa cccggactgc aagacgatcc 1020tgaaggccct gggcccagcg gctaccctag aggaaatgat gaccgcctgt cagggagtgg 1080gcggacccgg ccacaaggca cgcgtcctgg ctgaggccat gagccaggtg accaactccg 1140ctaccatcat gatgcagcgc ggcaactttc ggaaccaacg caagatcgtc aagtgcttca 1200actgtggcaa agaagggcac acagcccgca actgcagggc ccctaggaaa aagggctgtt 1260ggaaatgtgg aaaggaagga caccaaatga aagattgtac tgagagacag gctaattttt 1320tagggaagat ctggccttcc cacaagggaa ggccagggaa ttttcttcag agcagaccag 1380agccaacagc cccaccagaa gagagcttca ggtttgggga agagacaaca actccctctc 1440agaagcagga gccgatagac aaggaactgt atcctttagc ttccctcaga tcactctttg 1500gcagcgaccc ctcgtcacaa taaagatagg ggggcagctc aaggaggctc tcctggacac 1560cggagcagac gacaccgtgc tggaggagat gtcgttgcca ggccgctgga agccgaagat 1620gatcggggga atcggcggtt tcatcaaggt gcgccagtat gaccagatcc tcatcgaaat 1680ctgcggccac aaggctatcg gtaccgtgct ggtgggcccc acacccgtca acatcatcgg 1740acgcaacctg ttgacgcaga tcggttgcac gctgaacttc cccattagcc ctatcgagac 1800ggtaccggtg aagctgaagc ccgggatgga cggcccgaag gtcaagcaat ggccattgac 1860agaggagaag atcaaggcac tggtggagat ttgcacagag atggaaaagg aagggaaaat 1920ctccaagatt gggcctgaga acccgtacaa cacgccggtg ttcgcaatca agaagaagga 1980ctcgacgaaa tggcgcaagc tggtggactt ccgcgagctg aacaagcgca cgcaagactt 2040ctgggaggtt cagctgggca tcccgcaccc cgcagggctg aagaagaaga aatccgtgac 2100cgtactggat gtgggtgatg cctacttctc cgttcccctg gacgaagact tcaggaagta 2160cactgccttc acaatccctt cgatcaacaa cgagacaccg gggattcgat atcagtacaa 2220cgtgctgccc cagggctgga aaggctctcc cgcaatcttc cagagtagca tgaccaaaat 2280cctggagcct ttccgcaaac agaaccccga catcgtcatc tatcagtaca tggatgactt 2340gtacgtgggc tctgatctag agatagggca gcaccgcacc aagatcgagg agctgcgcca 2400gcacctgttg aggtggggac tgaccacacc cgacaagaag caccagaagg agcctccctt 2460cctctggatg ggttacgagc tgcaccctga caaatggacc gtgcagccta tcgtgctgcc 2520agagaaagac agctggactg tcaacgacat acagaagctg gtggggaagt tgaactgggc 2580cagtcagatt tacccaggga ttaaggtgag gcagctgtgc aaactcctcc gcggaaccaa 2640ggcactcaca gaggtgatcc ccctaaccga ggaggccgag ctcgaactgg cagaaaaccg 2700agagatccta aaggagcccg tgcacggcgt gtactatgac ccctccaagg acctgatcgc 2760cgagatccag aagcaggggc aaggccagtg gacctatcag atttaccagg agcccttcaa 2820gaacctgaag accggcaagt acgcccggat gaggggtgcc cacactaacg acgtcaagca 2880gctgaccgag gccgtgcaga agatcaccac cgaaagcatc gtgatctggg gaaagactcc 2940taagttcaag ctgcccatcc agaaggaaac ctgggaaacc tggtggacag agtattggca 3000ggccacctgg attcctgagt gggagttcgt caacacccct cccctggtga agctgtggta 3060ccagctggag aaggagccca tagtgggcgc cgaaaccttc tacgtggatg gggccgctaa 3120cagggagact aagctgggca aagccggata cgtcactaac cggggcagac agaaggttgt 3180caccctcact gacaccacca accagaagac tgagctgcag gccatttacc tcgctttgca 3240ggactcgggc ctggaggtga acatcgtgac agactctcag tatgccctgg gcatcattca 3300agcccagcca gaccagagtg agtccgagct ggtcaatcag atcatcgagc agctgatcaa 3360gaaggaaaag gtctatctgg cctgggtacc cgcccacaaa ggcattggcg gcaatgagca 3420ggtcgacaag ctggtctcgg ctggcatcag gaaggtgcta ttcctggatg gcatcgacaa 3480ggcccaggac gagcacgaga aataccacag caactggcgg gccatggcta gcgacttcaa 3540cctgccccct gtggtggcca aagagatcgt ggccagctgt gacaagtgtc agctcaaggg 3600cgaagccatg catggccagg tggactgtag ccccggcatc tggcaactcg attgcaccca 3660tctggagggc aaggttatcc tggtagccgt ccatgtggcc agtggctaca tcgaggccga 3720ggtcattccc gccgaaacag ggcaggagac agcctacttc ctcctgaagc tggcaggccg 3780gtggccagtg aagaccatcc atactgacaa tggcagcaat ttcaccagtg ctacggttaa 3840ggccgcctgc tggtgggcgg gaatcaagca ggagttcggg atcccctaca atccccagag 3900tcagggcgtc gtcgagtcta tgaataagga gttaaagaag attatcggcc aggtcagaga 3960tcaggctgag catctcaaga ccgcggtcca aatggcggta ttcatccaca atttcaagcg 4020gaaggggggg attggggggt acagtgcggg ggagcggatc gtggacatca tcgcgaccga 4080catccagact aaggagctgc aaaagcagat taccaagatt cagaatttcc gggtctacta 4140cagggacagc agaaatcccc tctggaaagg cccagcgaag ctcctctgga agggtgaggg 4200ggcagtagtg atccaggata atagcgacat caaggtggtg cccagaagaa aggcgaagat 4260cattagggat tatggcaaac agatggcggg tgatgattgc gtggcgagca gacaggatga 4320ggattag 4327 15 22 RNA Artificial Sequence Description of Artificial Sequence Illustrative helix II sequence 15cugaugaggc cgaaaggccg aa 22 16 22 RNA Human immunodeficiency virus type 1 16uaguaagaau guauagcccu ac 22 17 22 RNA Human immunodeficiency virus type 1 17aacccagauu guaagacuau uu 22 18 22 RNA Human immunodeficiency virus type 1 18uguuucaauu guggcaaaga ag 22 19 22 RNA Human immunodeficiency virus type 1 19aaaaagggcu guuggaaaug ug 22 20 22 RNA Human immunodeficiency virus type 1 20acgaccccuc gucacaauaa ag 22 21 22 RNA Human immunodeficiency virus type 1 21ggaauuggag guuuuaucaa ag 22 22 22 RNA Human immunodeficiency virus type 1 22auauuuuuca guucccuuag au 22 23 22 RNA Human immunodeficiency virus type 1 23uggaugauuu guauguagga uc 22 24 22 RNA Human immunodeficiency virus type 1 24cuuuggaugg guuaugaacu cc 22 25 22 RNA Human immunodeficiency virus type 1 25cagcuggacu gucaaugaca ua 22 26 22 RNA Human immunodeficiency virus type 1 26aacuuucuau guagaugggg ca 22 27 22 RNA Human immunodeficiency virus type 1 27aaggccgccu guuggugggc ag 22 28 22 RNA Human immunodeficiency virus type 1 28uaagacagca guacaaaugg ca 22 29 30 DNA Artificial Sequence Description of Artificial Sequence Primer 29cagctgctcg agcagctgaa gcttgcatgc 30 30 34 DNA Artificial Sequence Description of Artificial Sequence Primer 30gtaagttatg taacggacga tatcttgtct tctt 34 31 37 DNA Artificial Sequence Description of Artificial Sequence Primer 31cgcatagtcg acgggcccgc cactgctaga gattttc 37 32 116 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 32tcgaggtcga ctggtggaca gggaaggatt cgaaccttcg aagtcgatga cgtagagaaa 60aaatggtggc agtagaagga ttcgaacctt cgaagtcgat gacgtcatcc ccgggc 116 33 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 33tcgaggtcga ctggtggaac tggaaggatt cgaaccttcg aagtcgatga cgttcctaaa 60aaatggtgaa tcatgaagga ttcgaacctt cgaagtcgat gacgtaatac 110 34 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 34tcgaggtcga ctggtgggcc ccgaaggatt cgaaccttcg aagtcgatga cgtggaaaaa 60aaatggtggg aagagaagga ttcgaacctt cgaagtcgat gacgttggcc 110 35 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 35tcgaggtcga ctggtgacag cagaaggatt cgaaccttcg aagtcgatga cgttcagaaa 60aaatggtgaa gcaagaagga ttcgaacctt cgaagtcgat gacgtagccc 110 36 110 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 36tcgaggtcga ctggtgtaag aagaaggatt cgaaccttcg aagtcgatga cgttataaaa 60aaatggtgac cggtgaagga ttcgaacctt cgaagtcgat gacgttatac 110 37 116 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 37tcgaggcatg cgtcgactgg tgggcctaga aggattcgaa ccttcgaagt cgatgacgtg 60cacaaaaaat ggtgaactac gaaggattcg aaccttcgaa gtcgatgacg tgtacc 116 38 12 DNA Human immunodeficiency virus type 1 38atgggtgcga ga 12 39 12 DNA Human immunodeficiency virus type 1 39gatgaggatt ag 12 40 12 DNA Artificial Sequence Description of Artificial Sequence gagpol-SYNgp-codon optimised gagpol sequence 40atgggcgccc gc 12 41 12 DNA Artificial Sequence Description of Artificial Sequence gagpol-SYNgp-codon optimised gagpol sequence 41gatgaggatt ag 12 42 12 DNA Human immunodeficiency virus type 1 42atgagagtga ag 12 43 12 DNA Human immunodeficiency virus type 1 43gctttgctat aa 12 44 12 DNA Artificial Sequence Description of Artificial Sequence SYNgp-160nm-codon optimised env sequence 44atgagggtga ag 12 45 12 DNA Artificial Sequence Description of Artificial Sequence SYNgp-160nm-codon optimised env sequence 45gcgctgctgt aa 12 46 34 RNA Human immunodeficiency virus type 1 46ggcucgaacu ugucgugguu aucguggaug uguc 34 47 63 RNA Artificial Sequence Description of Artificial Sequence EGS based on Tyrosol t-RNA 47cgauagcaga cucuaaaucu gccgucaucg acuucgaagg uucgaauccu ucccaggaca 60cca 63 48 66 RNA Artificial Sequence Description of Artificial Sequence Consensus EGS sequence 48nnnnnnnagc agacucuaaa ucugccguca ucgacuucga agguucgaau ccuucnnnnn 60ncacca 66 49 49 RNA Artificial Sequence Description of Artificial Sequence Consensus EGS sequence 49nnnnnnnacg ucaucgacuu cgaagguucg aauccuucnn nnnncacca 49 50 13 RNA Human immunodeficiency virus type 1 50gggccuauag cac 13 51 13 RNA Human immunodeficiency virus type 1 51gaacuacuag uac 13 52 13 RNA Human immunodeficiency virus type 1 52guaagaaugu aua 13 53 13 RNA Human immunodeficiency virus type 1 53gaccgguucu aua 13 54 13 RNA Human immunodeficiency virus type 1 54gacagcaugu cag 13 55 13 RNA Human immunodeficiency virus type 1 55gaagcaauga gcc 13 56 13 RNA Human immunodeficiency virus type 1 56gggccccuag gaa 13 57 13 RNA Human immunodeficiency virus type 1 57gggaagaucu ggc 13 58 13 RNA Human immunodeficiency virus type 1 58ggaacuguau ccu 13 59 13 RNA Human immunodeficiency virus type 1 59gaaucuauga aua 13 60 13 RNA Human immunodeficiency virus type 1 60ggacagguaa gag 13 61 13 RNA Human immunodeficiency virus type 1 61ggcaguauuc auc 13 62 46 DNA Artificial Sequence Description of Combined DNA/RNA Molecule Anti- HIV EGS construct 62gtgcacguca ucgacuucga agguucgaau ccuucuaggc ccacca 46 63 46 DNA Artificial Sequence Description of Combined DNA/RNA Molecule Anti- HIV EGS construct 63gtacacguca ucgacuucga agguucgaau ccuucguagu ucacca 46 64 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 64uauaacguca ucgacuucga agguucgaau ccuucuucuu acacca 46 65 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 65uauaacguca ucgacuucga agguucgaau ccuucaccgg ucacca 46 66 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 66cugaacguca ucgacuucga agguucgaau ccuucugcug ucacca 46 67 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 67ggcuacguca ucgacuucga agguucgaau ccuucuugcu ucacca 46 68 46 DNA Artificial Sequence Description of Combined DNA/RNA Molecule Anti- HIV EGS construct 68ttccacguca ucgacuucga agguucgaau ccuucggggc ccacca 46 69 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 69gccaacguca ucgacuucga agguucgaau ccuucucuuc ccacca 46 70 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 70aggaacguca ucgacuucga agguucgaau ccuuccaguu ccacca 46 71 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 71uauuacguca ucgacuucga agguucgaau ccuucuagau ucacca 46 72 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 72cucuacguca ucgacuucga agguucgaau ccuucccugu ccacca 46 73 46 RNA Artificial Sequence Description of Artificial Sequence Anti-HIV EGS construct 73gaugacguca ucgacuucga agguucgaau ccuucuacug ccacca 46

Claims

1. A viral vector system comprising:(i) a first nucleotide sequence and a second nucleotide sequence, wherein the first nucleotide sequence encodes an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence, or transcription product thereof, wherein the second nucleotide sequence encodes a viral polypeptide required for the assembly of viral particles; and (ii) a third nucleotide sequence encoding a viral polypeptide required for the assembly of viral particles, which third nucleotide sequence has a different nucleotide sequence than the second nucleotide sequence, such that the third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by the external guide sequence.

2. The viral vector system according to claim 1, further comprising at least one further nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of the second nucleotide sequence, or transcription product thereof, wherein the gene product is selected from an external guide sequence, a ribozyme and an anti-sense ribonucleic acid.

3. A viral vector production system comprising:(i) a viral genome comprising at least one first nucleotide sequence and a second nucleotide sequence, wherein the at least one first nucleotide sequence encodes a gene product capable of binding to and effecting the cleavage, directly or indirectly, of the second nucleotide sequence, or transcription product thereof, wherein the second nucleotide sequence encodes a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding a viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence than the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one gene product is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.

4. The viral vector production system according to claim 3, wherein, in addition to an external guide sequence, at least one gene product is selected from a ribozyme and an anti-sense ribonucleic acid.

5. The viral vector system according to claim 1, wherein the viral vector is a retroviral vector.

6. The viral vector system according to claim 5, wherein the retroviral vector is a lentiviral vector.

7. The viral vector system according to claim 6, wherein the lentiviral vector is an HIV vector.

8. The viral vector system according to claim 5, wherein the polypeptide required for the assembly of viral particles is selected from gag, pol and env proteins.

9. The viral vector system according to claim 8, wherein at least the gag and pol proteins are from a lentivirus.

10. The viral vector system according to claim 8, wherein the env protein is from a lentivirus.

11. The viral vector system according to claim 9, wherein the lentivirus is HIV.

12. The viral vector system according to claim 3, wherein the third nucleotide sequence is resistant to cleavage directed by the gene product as a result of one or more conservative alterations in the third nucleotide sequence, which remove cleavage sites recognised by the at least one gene product and/or binding sites for the at least one gene product.

13. The vital vector system according to claim 1, wherein the third nucleotide sequence is adapted to be resistant to cleavage by RNase P.

14. The viral vector system according to claim 1, wherein the third nucleotide sequence is codon optimised for expression in producer cells.

15. The viral vector system according to claim 14, wherein the producer cells are mammalian cells.

16. The viral vector system according to claim 1 comprising a plurality of first nucleotide sequences and third nucleotide sequences as defined in claim 1.

17. A viral particle comprising the viral vector genome as defined in claim 3 and one or more third nucleotide sequences as defined in claim 3.

18. A viral particle produced using the viral vector production system according to claim 3.

19. A method for producing a viral particle which method comprises introducing into a host cell (i) the viral genome as defined in claim 3 (ii) one or more third nucleotide sequences as defined in claim 3 and (iii) nucleotide sequences encoding essential viral packaging components not encoded by the one or more third nucleotide sequences.

20. A viral particle produced by the method of claim 19.

21. A pharmaceutical composition comprising the viral particle according to claim 17, together with a pharmaceutically acceptable carrier or diluent.

22. A method of treating a viral infection, comprising administering to a subject infected with a virus an effective amount of the viral system according to claim 1.